Bio-Rad Laboratories (BIO) 10-Q 7 May 20 2020 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Mar. 31, 2020	Apr. 29, 2020
Document Transition Report	false
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Shell Company	false
City Area Code	(510)
Document Quarterly Report	true
Entity Incorporation, State or Country Code	DE
Entity File Number	1-7928
Entity Registrant Name	BIO-RAD LABORATORIES, INC.
Entity Central Index Key	0000012208
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Document Type	10-Q
Document Period End Date	Mar. 31, 2020
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q1
Amendment Flag	false
Entity Small Business	false
Entity Tax Identification Number	94-1381833
Entity Address, Address Line One	1000 Alfred Nobel Drive,
Entity Address, City or Town	Hercules,
Entity Address, Country	CA
Entity Address, Postal Zip Code	94547
Local Phone Number	724-7000
Entity Emerging Growth Company	false
Common Class A [Member]
Title of 12(b) Security	Class A Common Stock, Par Value $0.0001 per share
Trading Symbol	BIO
Security Exchange Name	NYSE
Entity Common Stock, Shares Outstanding		24,567,292
Common Class B [Member]
Title of 12(b) Security	Class B Common Stock, Par Value $0.0001 per share
Trading Symbol	BIOb
Security Exchange Name	NYSE
Entity Common Stock, Shares Outstanding		5,080,867

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
ASSETS:
Cash and cash equivalents	$ 603,551	$ 660,672
Short-term investments	433,150	453,973
Restricted investments	5,560	5,560
Accounts receivable, net	380,476	392,672
Inventories:
Raw materials	104,017	109,570
Work in process	144,331	146,131
Finished goods	308,681	298,306
Total inventories	557,029	554,007
Prepaid expenses	94,787	102,331
Other current assets	8,034	10,940
Total current assets	2,082,587	2,180,155
Property, plant and equipment	1,361,722	1,382,172
Less: accumulated depreciation and amortization	(875,548)	(882,833)
Property, plant and equipment, net	486,174	499,339
Operating lease right-of-use assets	200,487	201,868
Goodwill, net	264,131	264,131
Purchased intangibles, net	138,317	145,525
Other investments	5,434,760	4,638,205
Other assets	77,903	79,636
Total assets	8,684,359	8,008,859
LIABILITIES AND STOCKHOLDERS' EQUITY:
Accounts payable, accrued payroll and employee benefits	118,221	107,014
Accrued payroll and employee benefits	130,202	180,084
Current maturities of long-term debt and notes payable	426,308	426,172
Income and other taxes payable	32,298	36,285
Current operating lease liabilities	34,440	35,365
Other current liabilities	127,785	120,575
Total current liabilities	869,254	905,495
Long-term debt, net of current maturities	12,205	13,579
Deferred Income Tax Liabilities, Net	1,161,112	997,787
Operating lease liabilities	175,452	176,018
Other long-term liabilities	173,257	160,923
Total liabilities	2,391,280	2,253,802
Stockholders' equity:
Additional paid-in capital	423,742	410,020
Retained earnings	6,156,691	5,470,779
Accumulated other comprehensive loss	(148,955)	(87,348)
Total stockholders' equity	6,293,079	5,755,057
Total liabilities and stockholders' equity	8,684,359	8,008,859
Common Class A [Member]
Stockholders' equity:
Common stock	2	2
Common Class B [Member]
Stockholders' equity:
Common stock	1	1
Treasury Class A [Member]
Stockholders' equity:
Treasury stock	$ (138,402)	$ (38,397)

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets Parenthetical - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Accounts receivable, less allowance for doubtful accounts	$ 23,147	$ 26,713
Common Class A [Member]
Common Stock, Shares, Issued	24,942,773	24,884,265
Common Stock, Shares, Outstanding	24,834,725	24,704,772
Common Class B [Member]
Common Stock, Shares, Issued	5,100,137	5,096,421
Common Stock, Shares, Outstanding	5,100,137	5,095,504
Treasury Class A [Member]
Treasury Stock, Shares	108,048	179,493
Treasury Class B [Member]
Treasury Stock, Shares	0	917

Condensed Consolidated Statemen

Condensed Consolidated Statements of Income (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Net sales	$ 571,644	$ 553,979
Cost of goods sold	254,276	242,217
Gross profit	317,368	311,762
Selling, general and administrative expense	193,692	207,581
Research and Development Expense	49,303	47,575
Segment profit (loss)	74,373	56,606
Interest expense	5,690	5,986
Foreign exchange (gains) losses, net	928	1,280
Marketable Securities, Unrealized (Gain) Loss	(827,671)	(1,059,230)
Other Nonoperating Income (Expense)	3,273	18,696
Income before income taxes	898,699	1,127,266
(Provision) benefit for income taxes	(212,787)	(262,071)
Net income attributable to Bio-Rad	$ 685,912	$ 865,195
Basic earnings per share:
Net income per share basic attributable to Bio-Rad	$ 22.97	$ 29.03
Weighted average common shares - basic	29,865	29,801
Diluted earnings per share:
Net income per share diluted attributable to Bio-Rad	$ 22.72	$ 28.74
Weighted average common shares - diluted	30,196	30,104

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Comprehensive Income (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Net Income (Loss) Attributable to Parent	$ 685,912	$ 865,195
Foreign currency translation adjustments	(62,011)	(36,402)
Other Comprehensive Income (Loss), Pension and Other Postretirement Benefit Plans, Adjustment, Net of Tax, Portion Attributable to Parent	731	359
Net unrealized holding gains (losses) on available-for-sale investments net of tax expense	(327)	2,036
Total other comprehensive income (loss) net of tax	(61,607)	(34,007)
Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest	$ 624,305	$ 831,188

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Cash flows from operating activities:
Cash received from customers	$ 569,001	$ 550,291
Cash paid to suppliers and employees	(509,683)	(507,160)
Interest paid, net	(231)	(459)
Income tax payments, net	(4,528)	(4,567)
Investment proceeds and miscellaneous receipts, net	3,912	4,496
Proceeds from forward foreign exchange contracts, net	4,337	342
Net cash provided by operating activities	62,808	42,943
Cash flows from investing activities:
Capital expenditures	(21,591)	(23,629)
Proceeds from dispositions of property, plant and equipment	38	74
Payments for purchases of marketable securities and investments	(98,151)	(95,375)
Proceeds from maturities of marketable securities and investments	67,710	82,573
Proceeds from Sale of Debt Securities, Available-for-sale	39,672	22,324
Payments for Previous Acquisition	0	(16,083)
(Payments for) proceeds from Other Investing Activities	(100)	7,403
Net cash used in investing activities	(12,422)	(22,713)
Cash flows from financing activities:
Payments on long-term borrowings	(1,415)	(237)
Payments of contingent consideration	(1,265)	(1,433)
Proceeds from Issuance of Common Stock	4,068	0
Proceeds from Sale of Treasury Stock	0	3,831
Payments for purchases of treasury stock	(100,005)	0
Net cash (used in) provided by financing activities	(98,617)	2,161
Effect of Exchange Rate on Cash and Cash Equivalents	(5,977)	1,982
Beginning Cash, Cash Equivalents, and Restricted Cash	662,651	434,164
Cash and cash equivalents	603,551	455,890
Restricted Cash, Current	3,110	113
Restricted Cash, Noncurrent	1,782	2,534
Ending Cash, Cash Equivalents, and Restricted Cash	608,443	458,537
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect	$ (54,208)	$ 24,373

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Stockholders' Equity Statement - USD ($) $ in Thousands	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Treasury Stock [Member]	Retained Earnings [Member]	AOCI Attributable to Parent [Member]
Total Stockholders' Equity at Dec. 31, 2018	$ 4,020,331	$ 3	$ 394,342	$ (49,129)	$ 3,722,073	$ (46,958)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net Income (Loss) Attributable to Parent	865,195				865,195
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent	(34,007)					(34,007)
APIC, Share-based Payment Arrangement, Increase for Cost Recognition	8,505		8,505
Treasury Stock Reissued at Lower than Repurchase Price	3,831			5,398	(1,567)
Proceeds from Issuance of Common Stock	0
Total Stockholders' Equity at Mar. 31, 2019	4,863,855	3	402,847	(43,731)	4,585,701	(80,965)
Total Stockholders' Equity at Dec. 31, 2019	5,755,057	3	410,020	(38,397)	5,470,779	(87,348)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net Income (Loss) Attributable to Parent	685,912				685,912
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent	(61,607)					(61,607)
APIC, Share-based Payment Arrangement, Increase for Cost Recognition	9,654		9,654
Proceeds from Issuance of Common Stock	4,068		4,068
Total Stockholders' Equity at Mar. 31, 2020	6,293,079	$ 3	$ 423,742	(138,402)	$ 6,156,691	$ (148,955)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Treasury Stock, Value, Acquired, Cost Method	$ (100,005)			$ (100,005)

1. Basis of Presentation and U

1. Basis of Presentation and Use of Estimates	3 Months Ended
	Mar. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization, Consolidation and Presentation of Financial Statements Disclosure	1. BASIS OF PRESENTATION AND USE OF ESTIMATES Basis of Presentation In this report, “Bio-Rad,” “we,” “us,” “the Company” and “our” refer to Bio-Rad Laboratories, Inc. and its subsidiaries. The accompanying unaudited condensed consolidated financial statements of Bio-Rad have been prepared in accordance with accounting principles generally accepted in the United States of America (GAAP) and reflect all adjustments which are, in the opinion of management, necessary to fairly state the results of the interim periods presented. All such adjustments are of a normal recurring nature. Results for the interim period are not necessarily indicative of the results for the entire year. The condensed consolidated balance sheet at December 31, 2019 has been derived from the audited consolidated financial statements at that date but does not include all of the information and footnotes required by GAAP for complete financial statements. The condensed consolidated financial statements should be read in conjunction with the notes to the consolidated financial statements contained in our Annual Report on Form 10-K for the year ended December 31, 2019 . We evaluate subsequent events and the evidence they provide about conditions existing at the date of the balance sheet as well as conditions that arose after the balance sheet date but through the date the financial statements are issued. The effects of conditions that existed at the balance sheet date are recognized in the financial statements. Events and conditions arising after the balance sheet date but before the financial statements are issued are evaluated to determine if disclosure is required to keep the financial statements from being misleading. To the extent such events and conditions exist, disclosures are made regarding the nature of events and the estimated financial effects of those events and conditions. Use of Estimates The preparation of the condensed consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingencies at the date of the financial statements as well as the reported amounts of revenues and expenses during the reporting periods. Bio-Rad bases its estimates on historical experience and on various other market-specific and other relevant assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ materially from those estimates. Revenue Recognition We recognize revenue from operations through the sale of products, services, and rental of instruments. Revenue from contracts with customers is recognized upon transfer of control of promised products or services to customers in an amount that reflects the consideration we expect to receive in exchange for those products or services. We enter into contracts that can include various combinations of products and services, which are generally accounted for as distinct performance obligations. Revenue is recognized net of any taxes collected from customers (sales tax, value added tax, etc.), which are subsequently remitted to government authorities. Our contracts from customers often include promises to transfer multiple products and services to a customer. Determining whether products and services are considered distinct performance obligations that should be accounted for separately versus together may require significant judgment, and may or may not impact the timing of revenue recognition. Revenue associated with equipment that requires factory installation is not recorded until installation is complete and customer acceptance, if required, has occurred. Certain equipment requires installation due to the fact that the instruments are being operated in a clinical/laboratory environment, and the installation services could result in modification of the equipment in order to ensure that the instruments are working according to specifications of the customer which are subject to validation tests upon completion of the installation. In these arrangements, which require factory installation, the delivery of the equipment and the installation are separate performance obligations. We will recognize the transaction price allocated to the equipment only upon customer acceptance, as the transfer of control has occurred in relation to the equipment at that point in time as the customer has the ability to direct the use of and obtain substantially all of the remaining benefits from the asset. The transaction price allocated to the installation services is also recognized upon completion of the services because without the completion of the installation services and related customer acceptance the customer cannot receive any of the benefits of the service. At the time revenue is recognized, a provision is recognized for estimated product returns as this right is considered variable consideration. Accordingly, when product revenues are recognized, the transaction price is reduced by the estimated amount of product returns. Service revenues on extended warranty contracts are recognized ratably over the life of the service agreement as a stand-ready performance obligation. For arrangements that include a combination of products and services, transaction prices are allocated to performance obligations based on stand-alone selling prices. The method used to determine the stand-alone selling prices for service revenues is based on the observable prices when the services have been sold separately. In those instances where the timing of revenue recognition differs from the timing of invoicing, we have determined that our contracts generally do not include a significant financing component. The primary purpose of our invoicing terms is to provide customers with simple and predictable methods of purchasing our products and services, not to either provide or receive financing to or from our customers. We record contract liabilities when cash payments are received or due in advance of our performance. We do not disclose the value of unsatisfied performance obligations for contracts with an original expected length of one year or less. Our payment terms vary by the type and location of our customer, and the products and services offered. The term between invoicing and when payment is due is not significant. Reagent Rental Agreements Reagent rental agreements are a diagnostic industry sales method that provides use of an instrument and consumables (reagents) to a customer on a per test basis. These agreements may also include maintenance of the underlying instruments retained at customer locations as well as initial training. We initially determine if a reagent rental arrangement contains a lease at lease commencement. Where we have determined that such an arrangement contains a lease, we next must ascertain its lease classification for purposes of applying appropriate accounting treatment as an operating, sales-type or direct financing lease. In addition, for purposes of determining the lease term used in performing the lease classification test, we include the noncancellable period of the lease together with those periods covered by the option to extend the lease if the customer is reasonably certain to exercise that option, the periods covered by an option to terminate the lease if the customer is reasonably certain not to exercise that option, and the periods covered by the option to extend (or not to terminate) the lease in which exercise of the option is controlled by the company. While most of our reagent rental arrangements contain either the option for a lessee to extend and/or cancel, the period in which the contract is enforceable is a very short period and therefore the lease term has been limited to the noncancellable period. Furthermore, it has historically been very rare for these arrangements to contain an option for the lessee to purchase the underlying asset. As discussed in Note 14, Leases, we adopted Accounting Standards Codification (ASC) 842, “Leases,” on a modified retrospective basis effective January 1, 2019 with practical expedients, and did not restate comparative prior periods. We concluded that the use of the instrument (referred to as “lease elements”) is not within the guidance of ASC 606 but rather ASC 842. Accordingly, we first allocate the transaction price between the lease elements and the non-lease elements based on relative standalone selling prices. The determination of the transaction price requires judgment and consideration of any fixed/minimum payments as well as estimates of variable consideration. After allocation, the amount of variable payments allocated to lease components will be recognized as income under ASC 842, while the amount of variable payments allocated to non-lease components will be recognized as income in accordance with ASC 606. Upon our adoption of ASC 842 in 2019, the maintenance services, along with the reagents, are now allocated to the non-lease elements and will be recognized as income in accordance with ASC 606. This change is in alignment with the requirements of ASC 842, and has resulted in a decrease in the amount of rental income and a corresponding increase in the amount of maintenance service revenue that is included in total reported Net sales in our condensed consolidated income statements. Generally, the terms of the arrangements result in the transfer of control on reagents upon either (i) when the consumables are delivered or (ii) when the consumables are consumed by the customer. Historically, our reagent rental arrangements have been predominantly comprised of variable lease payments that fluctuate depending on the volume of reagents purchased, as very few of such arrangements contain any fixed/minimum lease payments. Further, our reagent rental arrangements are predominantly classified as operating leases, and any sales-type leases represent in aggregate a very insignificant amount of lease income. Our reported lease income is primarily variable in nature and is recognized upon delivery or as the reagents are consumed by the customer or delivered. Revenue allocated to the lease elements of these reagent rental arrangements represents approximately 3% of total revenue for both the three months ended March 31, 2020 , and March 31, 2019 , and is included as part of Net sales in our Condensed Consolidated Statements of Income. Contract costs: As a practical expedient, we expense as incurred costs to obtain contracts as the amortization period would have been one year or less. These costs, recorded within Selling, general and administrative expense, include our internal sales force and certain partner sales incentive programs. Disaggregation of Revenue: The following table presents our revenues disaggregated by geographic region based primarily on the location of the use of the product or service (in millions, unaudited): Three Months Ended March 31, 2020 2019 Europe $ 195.7 $ 185.9 Asia 111.4 106.4 United States 229.5 226.1 Other (primarily Canada and Latin America) 35.0 35.6 Total net sales $ 571.6 $ 554.0 The disaggregation of our revenue by industry segment sources is presented in our Segment Information footnote (see Note 11). Deferred revenues represent mostly unrecognized fees billed or collected for extended service arrangements. Deferred revenues are generally recognized ratably over the term of the service contract as our performance obligation is fulfilled over the life of the arrangement. A majority of our deferred revenue balance is classified as current with an expected length of one year or less. The deferred revenue balance at December 31, 2019 and March 31, 2020 was $45.8 million and $50.9 million , respectively. We warrant certain equipment against defects in design, materials and workmanship, generally for a period of one year. Upon revenue recognition of that equipment, we establish, as part of Cost of goods sold, a provision for the expected costs of such warranty based on historical experience, specific warranty terms and customer feedback. Each quarter we reevaluate estimates to access the adequacy of recorded warranty liabilities. Warranty liabilities are included in Other current liabilities and Other long-term liabilities in the Condensed Consolidated Balance Sheets. Change in our warranty liability for the three month period ended March 31, 2020 and 2019 were as follows (in millions): Three Months Ended March 31, 2020 2019 Balance at beginning of period $ 9.0 $ 10.1 Provision for warranty 1.9 1.4 Actual warranty costs (2.7 ) (2.2 ) Balance at end of period $ 8.2 $ 9.3 Allowance for Doubtful Accounts In our evaluation of bad debt allowances, we have considered past events, current conditions and reasonable and supportable forecasts about the future. We have considered what, if any, differences in future economic conditions are anticipated from our historical loss experience and based on current economic conditions to result in our required allowance for doubtful accounts as of March 31, 2020 , while reflecting that our account receivable portfolio is heavily current in nature. The adjustments made to historical loss experience reflect current differences in asset-specific risk characteristics, including, for example, accounts receivable by customer type (public or government entity versus private entity) and by geographic location of customer. Components of our allowance for doubtful accounts were as follows (in millions): December 31, 2019 $ 20.2 Provision for expected credit losses (0.9 ) Write-offs charged against the allowance (0.5 ) Recoveries collected 0.1 March 31, 2020 $ 18.9 Implementation Costs for Cloud Computing Arrangements The balance of capitalized implementation costs for cloud computing arrangements, net of accumulated amortization, was $3.9 million and $3.1 million at March 31, 2020 and December 31, 2019 , respectively. These costs were primarily for business analytics software and were recorded in Other current assets and Other assets in the Condensed Consolidated Balance Sheet. Recent Accounting Pronouncements Adopted In March 2020, the FASB issued ASU No. 2020-04, Facilitation of the Effects of Reference Rate Reform on Financial Reporting (Topic 848). The ASU provides optional expedients and exceptions for applying GAAP to transactions affected by reference rate (e.g., LIBOR) reform if certain criteria are met, for a limited period of time to ease the potential burden in accounting for (or recognizing the effects of) reference rate reform on financial reporting. The ASU is effective as of March 12, 2020 through December 31, 2022. We will evaluate transactions or contract modifications occurring as a result of reference rate reform and determine whether to apply the optional guidance on an ongoing basis. The ASU is currently not expected to have a material impact on our consolidated financial statements. In August 2018, the FASB issued ASU 2018-13, "Fair Value Measurement (Topic 820): Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurements" (ASU 2018-13), which aims to improve the overall usefulness of disclosures to financial statement users and reduce unnecessary costs to companies when preparing fair value measurement disclosures. We adopted this standard effective January 1, 2020 the adoption of ASU 2018-02 did not have a material impact on our consolidated financial statements. In June 2016, the FASB issued ASU 2016-13, "Measurement of Credit Losses on Financial Instruments." ASU 2016-13 replaces the incurred loss approach with an expected loss model for instruments measured at amortized cost and requires entities to record allowances for available-for-sale debt securities rather than reduce the carrying amount as done under the former other-than-temporary impairment model. We adopted ASU 2016-13 as of January 1, 2020 using the cumulative effect transition method. We’ve evaluated our impacted instruments for credit quality indicators, and have determined that there is no cumulative effect transition adjustment to retained earnings as of our adoption date. ASU 2016-13 had an insignificant impact to our condensed consolidated financial statements for the three months ended March 31, 2020 . See also Note 3, Fair Value Measurements, and the section above under the caption “Allowance for Doubtful Accounts.” Recent Accounting Pronouncements to be Adopted In January 2020, the FASB issued ASU 2020-01, Clarifying the Interactions between Topic 321 Investments—Equity Securities, Topic 323 Investments—Equity Method and Joint Ventures, and Topic 815 Derivatives and Hedging. ASU 2020-01 clarifies that a company should consider observable transactions that require a company to either apply or discontinue the equity method of accounting under Topic 323 for the purposes of applying the measurement alternative in accordance with Topic 321 immediately before applying or upon discontinuing the equity method. ASU 2020-01 also clarifies that, when determining the accounting for certain forward contracts and purchased options a company should not consider, whether upon settlement or exercise, if the underlying securities would be accounted for under the equity method or fair value option. ASU 2020-01 is effective for fiscal years beginning after December 15, 2020. Early adoption is permitted, including interim periods for which financial statements have not been issued. We are currently evaluating the effect of ASU 2020-01. In December 2019, the FASB issued ASU 2019-12, "Simplifying the Accounting for Income Taxes," which eliminates certain exceptions within ASC 740, Income Taxes , and clarifies other aspects of the current guidance to promote consistency among reporting entities. ASU 2019-12 is effective for fiscal years beginning after December 15, 2020 and early adoption is permitted in any interim or annual period, with any adjustments reflected as of the beginning of the fiscal year of adoption. We are currently evaluating the effect of adopting this pronouncement on our financial statements and disclosures. In August 2018, the FASB issued ASU 2018-14, "Disclosure Framework - Changes to the Disclosure Requirements for Defined Benefit Plans." ASU 2018-14 eliminates and adds certain disclosures for defined benefit plans. ASU 2018-14 is effective for fiscal years ending after December 15, 2020 using a retrospective approach. Early adoption is permitted. We are currently evaluating the disclosures but do not expect ASU 2018-14 to have a material impact to our disclosures for defined benefit plans.

2. Acquisitions (Notes)

2. Acquisitions (Notes)	3 Months Ended
	Mar. 31, 2020
Business Combinations [Abstract]
Business Combination Disclosure [Text Block]	ACQUISITIONS In October 2019, we acquired all the issued and outstanding shares of a foreign distributor for approximately $4.2 million , which included cash payments at closing, net of closing cash, of $3.6 million , and $0.6 million in contingent consideration potentially payable to the sellers. In addition, we recorded a net gain of $0.4 million for the settlement of preexisting conditions concurrent with the acquisition that was recorded in Selling, general and administrative expense. The acquisition was included in our Clinical Diagnostics segment's results of operations from the acquisition date and was accounted for as a business combination. The amount of acquisition-related costs was minimal as Bio-Rad primarily represented itself during the acquisition process. Proforma financial statements are not provided as the acquisition is immaterial to Bio-Rad taken as a whole for the periods presented. The final allocation of the payments was $3.4 million to customer relationships, a definite-lived intangible, $0.2 million to deferred tax asset, $0.8 million to deferred tax liability related to the purchased intangible and $1.4 million to acquired net assets. The final allocation of payments was unchanged from our preliminary allocation for the period ended December 31, 2019.

3. Fair Value Measurements

3. Fair Value Measurements	3 Months Ended
	Mar. 31, 2020
Fair Value Disclosures [Abstract]
Fair Value Measurements	FAIR VALUE MEASUREMENTS We determine the fair value of an asset or liability based on the assumptions that market participants would use in pricing the asset or liability in an orderly transaction between market participants at the measurement date. The identification of market participant assumptions provides a basis for determining what inputs are to be used for pricing each asset or liability. A fair value hierarchy has been established which gives precedence to fair value measurements calculated using observable inputs over those using unobservable inputs. This hierarchy prioritizes the inputs into three broad levels as follows: • Level 1: Quoted prices in active markets for identical instruments • Level 2: Other significant observable inputs (including quoted prices in active markets for similar instruments) • Level 3: Significant unobservable inputs (including assumptions in determining the fair value of certain investments) Financial assets and liabilities carried at fair value and measured on a recurring basis as of March 31, 2020 are classified in the hierarchy as follows (in millions): Level 1 Level 2 Level 3 Total Financial assets carried at fair value: Cash equivalents: Commercial paper $ — $ 65.5 $ — $ 65.5 Asset-backed securities — 0.1 — 0.1 Time deposits 26.4 10.0 — 36.4 Money market funds 96.5 — — 96.5 Total cash equivalents (a) 122.9 75.6 — 198.5 Restricted investment 5.6 — — 5.6 Equity securities (b) 5,448.4 — — 5,448.4 Available-for-sale investments: Corporate debt securities — 198.4 — 198.4 U.S. government sponsored agencies — 100.9 — 100.9 Foreign government obligations — 5.6 — 5.6 Other foreign obligations — 2.1 — 2.1 Municipal obligations — 14.4 — 14.4 Asset-backed securities — 71.8 — 71.8 Total available-for-sale investments (c) — 393.2 — 393.2 Forward foreign exchange contracts (d) — 0.7 — 0.7 Total financial assets carried at fair value $ 5,576.9 $ 469.5 $ — $ 6,046.4 Financial liabilities carried at fair value: Forward foreign exchange contracts (e) $ — $ 1.3 $ — $ 1.3 Contingent consideration (f) — — 3.5 3.5 Total financial liabilities carried at fair value $ — $ 1.3 $ 3.5 $ 4.8 Financial assets and liabilities carried at fair value and measured on a recurring basis as of December 31, 2019 are classified in the hierarchy as follows (in millions): Level 1 Level 2 Level 3 Total Financial assets carried at fair value: Cash equivalents: Commercial paper $ — $ 42.9 $ — $ 42.9 Time deposits 31.2 10.0 — 41.2 Asset-backed securities — 0.1 — 0.1 Money market funds 69.9 — — 69.9 Total cash equivalents (a) 101.1 53.0 — 154.1 Restricted investment 5.6 — — 5.6 Equity securities (b) 4,664.4 — — 4,664.4 Available-for-sale investments: Corporate debt securities — 204.5 — 204.5 U.S. government sponsored agencies — 106.1 — 106.1 Foreign government obligations — 4.7 — 4.7 Other foreign obligations — 3.1 — 3.1 Municipal obligations — 11.6 — 11.6 Asset-backed securities — 72.9 — 72.9 Total available-for-sale investments (c) — 402.9 — 402.9 Forward foreign exchange contracts (d) — 0.9 — 0.9 Total financial assets carried at fair value $ 4,771.1 $ 456.8 $ — $ 5,227.9 Financial liabilities carried at fair value: Forward foreign exchange contracts (e) $ — $ 1.0 $ — $ 1.0 Contingent consideration (f) — — 4.9 4.9 Total financial liabilities carried at fair value $ — $ 1.0 $ 4.9 $ 5.9 (a) Cash equivalents are included in Cash and cash equivalents in the Condensed Consolidated Balance Sheets. (b) Equity securities are included in the following accounts in the Condensed Consolidated Balance Sheets (in millions): March 31, 2020 December 31, 2019 Short-term investments $ 40.1 $ 51.0 Other investments 5,408.3 4,613.4 Total $ 5,448.4 $ 4,664.4 The year-to-date unrealized gains on our equity securities as of March 31, 2020 were $827.7 million and were primarily due to our investment in Sartorius AG and are recorded in our Condensed Consolidated Statements of Income. We own shares of ordinary voting stock of Sartorius AG (Sartorius), of Goettingen, Germany, a process technology supplier to the biotechnology, pharmaceutical, chemical and food and beverage industries. We own over 37% of the outstanding voting shares (excluding treasury shares) of Sartorius as of March 31, 2020 . The Sartorius family trust and Sartorius family members hold a controlling interest of the outstanding voting shares. We do not have any representative or designee on Sartorius' board of directors, nor do we have the ability to exercise significant influence over the operating and financial policies of Sartorius. (c) Available-for-sale investments are included in the following accounts in the Condensed Consolidated Balance Sheets (in millions): March 31, 2020 December 31, 2019 Short-term investments $ 393.1 $ 402.8 Other investments 0.1 0.1 Total $ 393.2 $ 402.9 (d) Forward foreign exchange contracts in an asset position are included in Other current assets in the Condensed Consolidated Balance Sheets. (e) Forward foreign exchange contracts in a liability position are included in Other current liabilities in the Condensed Consolidated Balance Sheets. (f) Contingent consideration liability is included in the following accounts in the Condensed Consolidated Balance Sheets (in millions): March 31, 2020 December 31, 2019 Other current liabilities $ 3.5 $ 3.3 Other long-term liabilities — 1.6 Total $ 3.5 $ 4.9 During the first quarter of 2016, we recognized a contingent consideration liability upon our acquisition of a high performance analytical flow cytometer platform from Propel Labs. At the acquisition date, the amount of contingent consideration was determined based on a probability-weighted income approach related to the achievement of sales milestones, ranging from 39% to 20% for the calendar years 2017 through 2020 . The sales milestones could potentially range from $0 to an unlimited amount. In the first quarter of 2020 , we paid $1.3 million per the purchase agreement. Since 2016 we have decreased the cumulative valuation of the sales milestones by net $13.9 million . The contingent consideration was accrued at its estimated fair value of $2.9 million as of March 31, 2020 . During the fourth quarter of 2019, we recognized a contingent consideration liability for earn-out targets related to our acquisition of a foreign distributor. The first earn-out payment of $0.7 million was paid by the acquisition date and the remaining payment is due in the second quarter of 2020. The maximum earn-out payment due is $1.4 million . The contingent consideration was accrued at its estimated fair value of $0.6 million as of March 31, 2020 . The following table provides a reconciliation of the Level 3 contingent consideration liabilities measured at estimated fair value (in millions): December 31, 2019 $ 4.9 Analytical flow cytometer platform: Payment of sales milestone (1.3 ) Decrease in estimated fair value of contingent consideration included in Selling, general and administrative expense (0.1 ) Foreign distributor earn-outs: Change in estimated fair value of contingent consideration included in Selling, general and administrative expense — March 31, 2020 $ 3.5 To estimate the fair value of Level 2 debt securities as of March 31, 2020 , our primary pricing provider uses Reuters as the primary pricing source. Our pricing process allows us to select a hierarchy of pricing sources for securities held. If Reuters does not price a Level 2 security that we hold, then the pricing provider will utilize our custodian supplied pricing as the secondary pricing source. For all commercial paper as of March 31, 2020 , our primary pricing provider uses Reuters in the hierarchy to determine pricing. Our pricing provider performs daily reasonableness testing of the Reuters prices. Price changes of 5% or greater compared to the previous day are investigated and resolved. In addition, we perform a quarterly testing of the Reuters prices to custodian reported prices. Price differences outside a tolerable variance of approximately 1% are investigated and resolved. Available-for-sale investments consist of the following (in millions): March 31, 2020 Amortized Cost Unrealized Gains Unrealized Losses Allowances for Credit Losses Fair Value Short-term investments: Corporate debt securities $ 199.2 $ 0.9 $ (1.7 ) $ — $ 198.4 Municipal obligations 14.3 0.1 — — 14.4 Asset-backed securities 72.2 0.2 (0.7 ) — 71.7 U.S. government sponsored agencies 98.1 2.8 — — 100.9 Foreign government obligations 5.6 — — — 5.6 Other foreign obligations 2.1 — — — 2.1 391.5 4.0 (2.4 ) — 393.1 Long-term investments: Asset-backed securities 0.1 — — — 0.1 0.1 — — — 0.1 Total $ 391.6 $ 4.0 $ (2.4 ) $ — $ 393.2 The following is a summary of the amortized cost and estimated fair value of our debt securities at March 31, 2020 by contractual maturity date (in millions): Amortized Cost Estimated Fair Value Mature in less than one year $ 163.8 $ 163.9 Mature in one to five years 167.3 167.6 Mature in more than five years 60.5 61.7 Total $ 391.6 $ 393.2 Available-for-sale investments consist of the following (in millions): December 31, 2019 Amortized Cost Unrealized Gains Unrealized Losses Estimated Fair Value Short-term investments: Corporate debt securities $ 203.2 $ 1.4 $ (0.1 ) $ 204.5 Municipal obligations 11.5 0.1 — 11.6 Asset-backed securities 72.7 0.2 (0.1 ) 72.8 U.S. government sponsored agencies 105.6 0.7 (0.2 ) 106.1 Foreign government obligations 4.7 — — 4.7 Other foreign obligations 3.1 — — 3.1 400.8 2.4 (0.4 ) 402.8 Long-term investments: Asset-backed securities 0.1 — — 0.1 0.1 — — 0.1 Total $ 400.9 $ 2.4 $ (0.4 ) $ 402.9 The following is a summary of investments with gross unrealized losses and the associated fair value (in millions): March 31, 2020 Less than 12 months Greater than 12 months Total Description of securities: Fair Value Unrealized Losses Fair Value Unrealized Losses Fair Value Unrealized Losses Corporate debt securities $ 106.0 $ 1.7 $ — $ — $ 106.0 $ 1.7 Asset-backed securities 55.2 0.6 3.7 0.1 58.9 0.7 Total $ 161.2 $ 2.3 $ 3.7 $ 0.1 $ 164.9 $ 2.4 December 31, 2019 Less than 12 months Greater than 12 months Total Description of securities: Fair Value Unrealized Losses Fair Value Unrealized Losses Fair Value Unrealized Losses Corporate debt securities $ 46.5 $ 0.1 $ 2.1 $ — $ 48.6 $ 0.1 Asset-backed securities 17.9 — 7.0 0.1 24.9 0.1 U.S government sponsored agencies 27.5 0.2 10.8 — 38.3 0.2 Total $ 91.9 $ 0.3 $ 19.9 $ 0.1 $ 111.8 $ 0.4 The unrealized losses of $2.4 million as of March 31, 2020 are due to a number of factors, including changes in interest rates, changes in economic conditions and changes in market outlook for various industries, among others. As outlined in Note 1, we adopted ASU 2016-13 as of January 1, 2020. ASU 2016-13 replaces the incurred loss approach with an expected loss model for instruments measured at amortized cost and requires entities to record allowances for available-for-sale debt securities rather than reduce the carrying amount as done under the former other-than-temporary impairment model. After further evaluation, we have concluded that all payments related to our available-for-sale investments are expected to be made in full and on time at par value. The diminution of value in the intervening period is due to market conditions such as illiquidity and interest rate movements and not due to significant, inherent credit concerns surrounding the issuer. The factors we considered in our evaluation included t he extent to which the fair value is less than the amortized cost basis, adverse conditions specifically related to the debt security, an industry or geographic area, and any changes in the rating of a security by a rating agency. Credit loss impairments are limited to the amount that the fair value of an instrument is less than its amortized cost basis. Given the nature of the securities in our available-for-sale investments portfolio, based on our expectation that all of the securities in the portfolio will pay on time and in full, and based on the limited extent to which the fair value of the securities in our available-for-sale investments portfolio are below the amortized cost basis, we do not anticipate any credit impairment losses in the portfolio at this time. As a result, we have no allowances for credit losses on our available-for-sale investments portfolio as of March 31, 2020 . Included in Other current assets are $1.9 million and $2.0 million of interest receivable as of March 31, 2020 and December 31, 2019, respectively, primarily associated with securities in our available-for-sale investments portfolio. Associated interest on these securities is typically payable semi-annually. Due to the short-term nature of our interest receivable asset, we have made an accounting policy election not to measure an allowance for credit losses for accrued interest receivable. We consider any uncollected interest receivable that is overdue greater than one year to be impaired for purposes of write-off, and we have not experienced any such credit losses. As part of distributing our products, we regularly enter into intercompany transactions. We enter into forward foreign exchange contracts to manage foreign exchange risk of future movements in foreign exchange rates that affect foreign currency denominated intercompany receivables and payables. We do not use derivative financial instruments for speculative or trading purposes. We do not seek hedge accounting treatment for these contracts. As a result, these contracts, generally with maturity dates of 90 days or less and denominated primarily in currencies of industrial countries, are recorded at their fair value at each balance sheet date. The notional principal amounts provide one measure of the transaction volume outstanding as of March 31, 2020 and do not represent the amount of Bio-Rad's exposure to loss. The estimated fair value of these contracts was derived using the spot rates from Reuters on the last business day of the quarter and the points provided by counterparties. The resulting gains or losses offset exchange gains or losses on the related receivables and payables, both of which are included in Foreign currency exchange losses, net in the Condensed Consolidated Statements of Income. The following is a summary of our forward foreign exchange contracts (in millions): March 31, 2020 Contracts maturing in April through June 2020 to sell foreign currency: Notional value $ 58.6 Unrealized gain $ 0.2 Contracts maturing in April through June 2020 to purchase foreign currency: Notional value $ 237.1 Unrealized loss $ (0.9 ) The estimated fair value of our current maturities of long-term debt, excluding leases, as of March 31, 2020 and December 31, 2019 that is not recognized at fair value in the Condensed Consolidated Balance Sheets has an estimated fair value based on quoted market prices for the same or similar issues. The estimated fair value of our long-term debt discussed above and the level of the fair value hierarchy within which the fair value measurement is categorized are as follows (in millions): March 31, 2020 December 31, 2019 Carrying Amount Estimated Fair Value Fair Value Hierarchy Level Carrying Amount Estimated Fair Value Fair Value Hierarchy Level Total current maturities long-term debt, excluding leases $ 424.5 $ 422.9 2 $ 424.4 $ 435.5 2 Included in Other Investments in the Condensed Consolidated Balance Sheet are investments without readily determinable fair value measured at cost with adjustments for observable price changes in price or impairments. The carrying value of these investments was $0.5 million and $0.3 million as of March 31, 2020 and December 31, 2019

4. Intangible Assets, Goodwill

4. Intangible Assets, Goodwill and Other	3 Months Ended
	Mar. 31, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets Disclosure	GOODWILL AND OTHER PURCHASED INTANGIBLE ASSETS Changes to goodwill by segment were as follows (in millions): Life Science Clinical Diagnostics Total Balances as of December 31, 2019: Goodwill $ 250.1 $ 349.2 $ 599.3 Accumulated impairment losses (41.8 ) (293.4 ) (335.2 ) Goodwill, net 208.3 55.8 264.1 Acquisitions — — — Balances as of March 31, 2020: Goodwill 250.1 349.2 599.3 Accumulated impairment losses (41.8 ) (293.4 ) (335.2 ) Goodwill, net $ 208.3 $ 55.8 $ 264.1 In conjunction with the purchase of all the issued and outstanding shares of a foreign distributor in October 2019 (see Note 2, "Acquisitions"), we recorded $3.4 million of Customer relationships, a definite-lived intangible assets. Information regarding our identifiable purchased intangible assets with definite and indefinite lives is as follows (in millions): March 31, 2020 Weighted-Average Remaining Amortization Period (years) Purchase Price Accumulated Amortization Net Carrying Amount Customer relationships/lists 6.26 $ 105.1 $ (74.5 ) $ 30.6 Know how 5.48 187.0 (162.4 ) 24.6 Developed product technology 8.14 142.1 (94.4 ) 47.7 Licenses 8.51 76.0 (45.2 ) 30.8 Tradenames 8.34 6.4 (3.7 ) 2.7 Covenants not to compete 5.76 3.1 (1.4 ) 1.7 Other — 0.1 (0.1 ) — Total definite-lived intangible assets 519.8 (381.7 ) 138.1 In-process research and development 0.2 — 0.2 Total purchased intangible assets $ 520.0 $ (381.7 ) $ 138.3 December 31, 2019 Weighted-Average Remaining Amortization Period (years) Purchase Price Accumulated Amortization Net Carrying Amount Customer relationships/lists 6.36 $ 107.2 $ (74.3 ) $ 32.9 Know how 5.71 188.5 (162.6 ) 25.9 Developed product technology 8.31 144.2 (93.9 ) 50.3 Licenses 8.74 76.0 (44.4 ) 31.6 Tradenames 8.50 6.4 (3.6 ) 2.8 Covenants not to compete 6.01 3.2 (1.4 ) 1.8 Other — 0.1 (0.1 ) — Total definite-lived intangible assets 525.6 (380.3 ) 145.3 In-process research and development 0.2 — 0.2 Total purchased intangible assets $ 525.8 $ (380.3 ) $ 145.5 Amortization expense related to purchased intangible assets is as follows (in millions): Three Months Ended March 31, 2020 2019 Amortization expense $ 5.9 $ 5.5

5. Supplemental Cash Flow Info

5. Supplemental Cash Flow Information (Notes)	3 Months Ended
	Mar. 31, 2020
Supplemental Cash Flow Elements [Abstract]
Cash Flow, Supplemental Disclosures [Text Block]	SUPPLEMENTAL CASH FLOW INFORMATION The reconciliation of net income to net cash provided by operating activities is as follows (in millions): Three Months Ended March 31, 2020 March 31, 2019 Net income $ 685.9 $ 865.2 Adjustments to reconcile net income to net cash provided by operating activities: Depreciation and amortization 33.6 32.9 Reduction in the carrying amount of right-of-use assets 9.6 10.0 Share-based compensation 9.7 8.5 Gains on dispositions of securities (0.4 ) — Other-than-temporary impairment losses on investment — 1.6 Changes in fair market value of equity securities (827.7 ) (1,059.2 ) Losses on dispositions of fixed assets 0.1 0.3 Changes in fair value of contingent consideration (0.1 ) (0.5 ) Payments for operating lease liabilities (9.3 ) (11.7 ) Decrease (increase) in accounts receivable 2.2 (2.0 ) Increase in inventories (13.7 ) (11.6 ) Increase in other current assets (9.5 ) (16.7 ) (Decrease) increase in accounts payable and other current liabilities (25.6 ) 20.6 Increase in income taxes payable 20.9 13.8 Increase in deferred income taxes 171.8 238.5 Increase (decrease) in other long term liabilities 15.7 (38.3 ) Other (0.4 ) (8.5 ) Net cash provided by operating activities $ 62.8 $ 42.9 Non-cash investing activities: Purchased property, plant and equipment $ 6.0 $ 5.1 Purchased marketable securities and investments $ 2.7 $ —

6. Long-Term Debt

6. Long-Term Debt	3 Months Ended
	Mar. 31, 2020
Debt Disclosure [Abstract]
Long-term Debt	LONG-TERM DEBT The principal components of long-term debt are as follows (in millions): March 31, December 31, 4.875% Senior Notes due 2020 principal amount $ 425.0 $ 425.0 Less unamortized discount and debt issuance costs (0.5 ) (0.6 ) 4.875% Senior Notes less unamortized discount and debt issuance costs 424.5 424.4 Finance leases and other debt 14.0 15.4 438.5 439.8 Less current maturities (426.3 ) (426.2 ) Long-term debt $ 12.2 $ 13.6 Senior Notes due 2020 In December 2010, Bio-Rad sold $425.0 million principal amount of Senior Notes due December 2020 ( 4.875% Notes). The sale yielded net cash proceeds of $422.6 million at an effective rate of 4.946% . The 4.875% Notes pay a fixed rate of interest of 4.875% per year. We have the option to redeem any or all of the 4.875% Notes at any time at a redemption price of 100% of the principal amount (plus a specified make-whole premium as defined in the indenture governing the 4.875% Notes) and accrued and unpaid interest thereon to the redemption date. Our obligations under the 4.875% Notes are not secured and rank equal in right of payment with all of our existing and future unsubordinated indebtedness. Certain covenants apply at each year end to the 4.875% Notes including limitations on the following: liens, sale and leaseback transactions, mergers, consolidations or sales of assets and other covenants. We were in compliance with these covenants as of March 31, 2020 . There are no restrictive covenants relating to total indebtedness, interest coverage, stock repurchases, recapitalizations, dividends and distributions to shareholders or current ratios. Credit Agreement In April 2019, Bio-Rad entered into a $200 million unsecured Credit Agreement. Borrowings under the Credit Agreement are on a revolving basis and can be used to make permitted acquisitions, for working capital and for other general corporate purposes. We had no outstanding borrowings under the Credit Agreement as of March 31, 2020 ; however, $0.2 million was utilized for domestic standby letters of credit that reduced our borrowing availability as of March 31, 2020 . The Credit Agreement matures in April 2024. If we had borrowed against our Credit Agreement, the borrowing rate would have been 2.555% at March 31, 2020 , which is based on the 3-month LIBOR. The Credit Agreement requires Bio-Rad to comply with certain financial ratios and covenants, among other things. These ratios and covenants include a leverage ratio test and an interest coverage test, as well as restrictions on our ability to declare or pay dividends, incur debt, guarantee debt, enter into transactions with affiliates, merge or consolidate, sell assets, make investments and create liens. We were in compliance with all of these ratios and covenants as of March 31, 2020 .

7. Accumulated Other Comprehen

7. Accumulated Other Comprehensive Income 7. Accumulated Other Comprehensive Income (Notes)	3 Months Ended
	Mar. 31, 2020
Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]
Stockholders' Equity Note Disclosure [Text Block]	. ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) Accumulated other comprehensive income included in our Condensed Consolidated Balance Sheets consists of the following components (in millions): Foreign currency translation adjustments Foreign other post-employment benefits adjustments Net unrealized holding gains on available-for-sale investments Total accumulated other comprehensive income (loss) Balances as of January 1, 2020: $ (72.4 ) $ (22.2 ) $ 7.2 $ (87.4 ) Other comprehensive (loss) income, before reclassifications (62.9 ) 0.2 — (62.7 ) Amounts reclassified from Accumulated other comprehensive income — 0.3 (0.4 ) (0.1 ) Income tax effects 0.9 0.2 0.1 1.2 Other comprehensive (loss) income, net of income taxes (62.0 ) 0.7 (0.3 ) (61.6 ) Balances as of March 31, 2020: $ (134.4 ) $ (21.5 ) $ 6.9 $ (149.0 ) Foreign currency translation adjustments Foreign other post-employment benefits adjustments Net unrealized holding gains on available-for-sale investments Total accumulated other comprehensive income (loss) Balances as of January 1, 2019: $ (35.5 ) $ (14.8 ) $ 3.3 $ (47.0 ) Other comprehensive (loss) income, before reclassifications (36.4 ) 0.2 2.0 (34.2 ) Amounts reclassified from Accumulated other comprehensive income — 0.2 — 0.2 Income tax effects — — — — Other comprehensive (loss) income, net of income taxes (36.4 ) 0.4 2.0 (34.0 ) Balances as of March 31, 2019: $ (71.9 ) $ (14.4 ) $ 5.3 $ (81.0 ) The reclassification adjustments are calculated using the specific identification method. The impact to income before taxes for amounts reclassified out of Accumulated other comprehensive income into the Condensed Consolidated Statements of Income, with presentation location, were as follows (in millions): Three Months Ended March 31, Components of Comprehensive income 2020 2019 Location Amortization of foreign other post-employment benefit items $ (0.3 ) $ (0.2 ) Other (income) expense, net Net holding gains on equity securities and available-for-sale investments $ 0.4 $ — Other (income) expense, net

8. Earnings Per Share

8. Earnings Per Share	3 Months Ended
	Mar. 31, 2020
Earnings Per Share [Abstract]
Earnings Per Share	. EARNINGS PER SHARE Basic earnings per share is computed by dividing net income attributable to Bio-Rad by the weighted average number of common shares outstanding for that period. Diluted earnings per share takes into account the effect of dilutive instruments, such as stock options and restricted stock, and uses the average share price for the period in determining the number of potential common shares that are to be added to the weighted average number of shares outstanding. Potential common shares are excluded from the diluted earnings per share calculation if the effect of including such securities would be anti-dilutive. The weighted average number of common shares outstanding used to calculate basic and diluted earnings per share, and the anti-dilutive shares that are excluded from the diluted earnings per share calculation are as follows (in thousands): Three Months Ended March 31, 2020 2019 Basic weighted average shares outstanding 29,865 29,801 Effect of potentially dilutive stock options and restricted stock awards 331 303 Diluted weighted average common shares 30,196 30,104 Anti-dilutive shares 62 226

9. Other Income and Expenses

9. Other Income and Expenses	3 Months Ended
	Mar. 31, 2020
Other Income and Expenses [Abstract]
Other Income and Other Expense Disclosure	. OTHER INCOME AND EXPENSE, NET Other (income) expense, net includes the following components (in millions): Three Months Ended March 31, 2020 2019 Interest and investment income $ (2.8 ) $ (19.5 ) Net realized gain on investments (0.4 ) — Other-than-temporary impairment loss on investment — 1.6 Other (income) expense (0.1 ) (0.8 ) Other (income) expense, net $ (3.3 ) $ (18.7 )

10. Income Taxes

10. Income Taxes	3 Months Ended
	Mar. 31, 2020
Income Tax Disclosure [Abstract]
Income Taxes	. INCOME TAXES Our effective income tax rate was 23.7% and 23.2% for the three months ended March 31, 2020 and 2019 , respectively. The higher income tax rate in 2020 was partly driven by the reassessment of a tax position taken in a prior year. The realization of deferred tax assets is dependent upon the generation of sufficient taxable income of the appropriate character in future periods. We regularly assess our ability to realize our deferred tax assets and establish a valuation allowance if it is more likely than not that some portion, or all, of our deferred tax assets will not be realized. In assessing the realizability of our deferred tax assets, we weigh all available positive and negative evidence. Due to the weight of objectively verifiable negative evidence, we believe that it is more likely than not that our California and certain foreign deferred tax assets will not be realized as of March 31, 2020 , and have maintained a valuation allowance on such deferred tax assets. Our income tax returns are routinely audited by U.S. federal, state and foreign tax authorities. We are currently under examination by many of these tax authorities. There are differing interpretations of tax laws and regulations, and as a result, significant disputes may arise with these tax authorities involving issues around the timing and amount of deductions and allocations of income among various tax jurisdictions. We evaluate our exposures associated with our tax filing positions on a quarterly basis. We record liabilities for unrecognized tax benefits related to uncertain tax positions. We do not believe any currently pending uncertain tax positions will have a material adverse effect on our condensed consolidated financial statements, although an adverse resolution of one or more of these uncertain tax positions in any period may have a material impact on the results of operations for that period. Our gross unrecognized tax benefits were $51.7 million and $39.2 million as of March 31, 2020, and December 31, 2019, respectively. The net increase to our gross unrecognized tax benefits of $12.5 million is primarily the result of a reassessment of a tax position taken in a prior period as a result of new information obtained during the current period.

11. Segment Information Segmen

11. Segment Information Segment Reporting	3 Months Ended
	Mar. 31, 2020
Segment Reporting [Abstract]
Segment Reporting Disclosure [Text Block]	SEGMENT INFORMATION Information regarding industry segments for the three months ended March 31, 2020 and 2019 is as follows (in millions): Life Science Clinical Diagnostics Other Operations Segment net sales 2020 $ 227.2 $ 340.3 $ 4.1 2019 $ 215.7 $ 334.1 $ 4.2 Segment net profit (loss) 2020 $ 25.4 $ 46.2 $ 0.7 2019 $ 22.8 $ 30.9 $ (0.1 ) Segment results are presented in the same manner as we present our operations internally to make operating decisions and assess performance. Net corporate operating, interest and other expense for segment results consists of receipts and expenditures that are not the primary responsibility of segment operating management and therefore are not allocated to the segments for performance assessment by our chief operating decision maker. Interest expense is charged to segments based on the carrying amount of inventory and receivables employed by that segment. For the three months ended March 31, 2020 compared to the same period in 2019 , our Life Science segment had increased sales, partially offset by increased cost of goods sold, while our Clinical Diagnostics segment had increased sales, along with decreased selling, general and administrative expense. The following reconciles total segment profit to consolidated income before income taxes (in millions): Three Months Ended March 31, 2020 2019 Total segment profit $ 72.3 $ 53.6 Foreign currency exchange losses, net (0.9 ) (1.3 ) Net corporate operating, interest and other expense not allocated to segments (3.7 ) (2.9 ) Change in fair market value of equity securities 827.7 1,059.2 Other income (expense), net 3.3 18.7 Consolidated income before income taxes $ 898.7 $ 1,127.3

12. Legal Proceedings

12. Legal Proceedings	3 Months Ended
	Mar. 31, 2020
Loss Contingency, Information about Litigation Matters [Abstract]
Legal Proceedings.	12. LEGAL PROCEEDINGS We are a party to various claims, legal actions and complaints arising in the ordinary course of business. We cannot at this time reasonably estimate a range of exposure, if any, of the potential liability with respect to these matters. While we do not believe, at this time, that any ultimate liability resulting from any of these other matters will have a material adverse effect on our results of operations, financial position or liquidity, we cannot give any assurance regarding the ultimate outcome of these other matters and their resolution could be material to our operating results for any particular period, depending on the level of income for the period.

13. Restructuring Costs (Notes)

13. Restructuring Costs (Notes)	3 Months Ended
	Mar. 31, 2020
Restructuring Costs [Abstract]
Restructuring and Related Activities Disclosure [Text Block]	RESTRUCTURING COSTS Restructuring Costs for a Facility Closure In December 2018, we announced the closure of a small manufacturing facility outside Paris, France. From December 2018 to March 31, 2020 , total expenses were $4.0 million . Restructuring charges for the facility closure are included in our Clinical Diagnostics segment's results of operations. The liability of $2.9 million as of March 31, 2020 consisted of $2.7 million recorded in Accrued payroll and employee benefits and $0.2 million recorded in Other current liabilities in the Condensed Consolidated Balance Sheets. The following table summarizes the activity for the facility closure restructuring reserves for severance and exit costs (in millions): Balances as of December 31, 2019: $ 3.2 Cash payments (0.3 ) Balances as of March 31, 2020: $ 2.9 Restructuring Costs for European and North American Reorganization In November 2019, we announced our strategy-driven restructuring plan. We expect that a significant portion of the net savings resulting from this restructuring plan will be repurposed in alignment with our portfolio strategy. The restructuring plan includes a workforce reduction in Europe, the United States and Canada, and is expected to be incurred through 2020. The liability of $14.0 million as of March 31, 2020 was recorded in Accrued payroll and employee benefits in the Condensed Consolidated Balance Sheets. The amounts recorded were reflected in Cost of goods sold of $(1.5) million , in Selling, general and administrative expense of $(0.5) million and in Research and development expense of $(0.4) million in the Condensed Consolidated Statements of Income for the three months ended March 31, 2020 . From November 2019 to March 31, 2020 , total expenses were $22.9 million . The following table summarizes the activity of our European and North American reorganization restructuring reserves for severance (in millions): Life Science Clinical Diagnostics Total Balances as of December 31, 2019: $ 6.2 $ 19.1 $ 25.3 Adjustment to expense (0.3 ) (2.1 ) (2.4 ) Cash payments (2.9 ) (5.7 ) (8.6 ) Foreign currency translation gains (0.1 ) (0.2 ) (0.3 ) Balances as of March 31, 2020: $ 2.9 $ 11.1 $ 14.0

14. Leases (Notes)

14. Leases (Notes)	3 Months Ended
	Mar. 31, 2020
14. Leases [Abstract]
Leases of Lessee Disclosure [Text Block]	14. LEASES: FINANCE, AND OPERATING WHERE WE ACT AS LESSEE For operating leases where we act as lessor in reagent rental agreements, please see Note 1. We have operating leases and to a lesser extent finance leases, for buildings, vehicles and equipment. For operating leases, we have elected not to separate lease and non-lease components for buildings, vehicles and equipment. Our leases have remaining lease terms of 1 year to 19 years, which includes our determination to exercise renewal options. We determine if an arrangement is a lease at inception. Right-of-use (ROU) assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at the commencement date based on the present value of lease payments over the lease term. As our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. The operating lease ROU asset also includes any lease payments made and excludes lease incentives. Our lease terms may include options to extend or terminate the lease. For purposes of determining the lease term used in the measurement of operating lease ROU assets and operating lease liabilities, we include the noncancellable period of the lease together with those periods covered by the option to extend the lease if we are reasonably certain to exercise that option, the periods covered by an option to terminate the lease if we are reasonably certain not to exercise that option, and the periods covered by the option to extend (or to not terminate) the lease in which exercise of the option is controlled by the lessor. Lease expense for lease payments is recognized on a straight-line basis over the lease term. The components of lease expense were as follows (in millions): Three Months Ended Three Months Ended March 31, March 31, 2020 2019 Operating lease cost $ 12.6 $ 12.4 Finance lease cost: Amortization of right-of-use assets $ 0.1 $ 0.1 Interest on lease liabilities 0.2 0.2 Total finance lease cost $ 0.3 $ 0.3 Sublease income $ 0.7 $ 0.7 The sublease is for a building with a term that ends in 2025, with no options to extend or renew. Operating lease cost includes original reduction in the carrying amount of ROU assets, the impact of remeasurements, modifications, impairments and abandonments. Historically, our short-term leases, reflecting leases with a lease term of one year or less, are not significant. Operating lease variable cost is primarily comprised of reimbursed actual common area maintenance, property taxes and insurance, which are immaterial. Supplemental cash flow information related to leases was as follows (in millions): Three Months Ended Three Months Ended March 31, March 31, 2020 2019 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 11.4 $ 11.7 Operating cash flows from finance leases $ 0.2 $ 0.2 Financing cash flows from finance leases $ 0.1 $ 0.2 Right-of-use assets obtained in exchange for lease obligations: Operating leases $ 10.8 $ 1.4 Finance leases $ — $ — Supplemental balance sheet information related to leases was as follows (in millions): March 31, 2020 December 31, 2019 Operating Leases Operating lease right-of-use assets $ 200.5 $ 201.9 Current operating lease liabilities $ 34.4 $ 35.4 Operating lease liabilities 175.5 176.0 Total operating lease liabilities $ 209.9 $ 211.4 Finance leases are included in Property, plant and equipment, Current maturities of long-term debt, and Long-term debt, net of current maturities. March 31, 2020 December 31, 2019 Finance Leases Property, plant and equipment, gross $ 11.4 $ 11.4 Less: accumulated depreciation and amortization (4.3 ) (4.2 ) Property, plant and equipment, net $ 7.1 $ 7.2 Current maturities of long-term debt and notes payable $ 0.5 $ 0.5 Long-term debt, net of current maturities 11.0 11.2 Total finance lease liabilities $ 11.5 $ 11.7 March 31, 2020 December 31, 2019 Weighted Average Remaining Lease Term Operating leases - in years 9 9 Finance leases - in years 18 18 Weighted Average Discount Rate Operating leases 4.1 % 4.2 % Finance leases 6.5 % 6.5 % Maturities of lease liabilities were as follows (in millions): Year Ending December 31, Operating Leases Finance Leases 2020 (excluding the three months ended March 31, 2020) $ 32.0 $ 1.2 2021 37.7 1.2 2022 30.5 1.1 2023 25.7 1.1 2024 23.0 1.1 Thereafter 105.0 14.9 Total lease payments 253.9 20.6 Less imputed interest (44.0 ) (9.1 ) Total $ 209.9 $ 11.5 As of March 31, 2020 , we have an additional lease for a facility in Fort Worth, Texas USA that has not commenced of $1.6 million . The operating lease will commence in either the second or third quarter of 2020 with a lease term of four years .

15. Subsequent Events (Notes)

15. Subsequent Events (Notes)	3 Months Ended
	Mar. 31, 2020
Subsequent Events [Abstract]
Subsequent Events [Text Block]	Subsequent Events Acquisition In April 2020, we acquired all the issued and outstanding stock of Celsee, Inc. for approximately $100 million and contingent consideration related to the achievement of sales milestones that could potentially range from $0 to $60 million . We believe this acquisition will complement our offerings in the Life Science products as Celsee, Inc. offers instruments and consumables for the isolation, detection, and analysis of single cells. The acquisition will be included in our Life Science segment's results of operations from the acquisition date and will be accounted for as a business acquisition. We have not yet allocated the purchase price to the acquired assets and liabilities. Sale of a Division In April 2020, we received $12.2 million

1. Basis of Presentation and_2

1. Basis of Presentation and Use of Estimates Basis of Presentation and Use of Estimates (Policies)	3 Months Ended
	Mar. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Receivables, Trade and Other Accounts Receivable, Allowance for Doubtful Accounts, Policy [Policy Text Block]	Allowance for Doubtful Accounts In our evaluation of bad debt allowances, we have considered past events, current conditions and reasonable and supportable forecasts about the future. We have considered what, if any, differences in future economic conditions are anticipated from our historical loss experience and based on current economic conditions to result in our required allowance for doubtful accounts as of March 31, 2020 , while reflecting that our account receivable portfolio is heavily current in nature. The adjustments made to historical loss experience reflect current differences in asset-specific risk characteristics, including, for example, accounts receivable by customer type (public or government entity versus private entity) and by geographic location of customer. Components of our allowance for doubtful accounts were as follows (in millions): December 31, 2019 $ 20.2 Provision for expected credit losses (0.9 ) Write-offs charged against the allowance (0.5 ) Recoveries collected 0.1 March 31, 2020 $ 18.9
Standard Product Warranty, Policy [Policy Text Block]	We warrant certain equipment against defects in design, materials and workmanship, generally for a period of one year. Upon revenue recognition of that equipment, we establish, as part of Cost of goods sold, a provision for the expected costs of such warranty based on historical experience, specific warranty terms and customer feedback. Each quarter we reevaluate estimates to access the adequacy of recorded warranty liabilities. Warranty liabilities are included in Other current liabilities and Other long-term liabilities in the Condensed Consolidated Balance Sheets. Change in our warranty liability for the three month period ended March 31, 2020 and 2019 were as follows (in millions): Three Months Ended March 31, 2020 2019 Balance at beginning of period $ 9.0 $ 10.1 Provision for warranty 1.9 1.4 Actual warranty costs (2.7 ) (2.2 ) Balance at end of period $ 8.2 $ 9.3
New Accounting Pronouncements, Policy [Policy Text Block]	Recent Accounting Pronouncements Adopted In March 2020, the FASB issued ASU No. 2020-04, Facilitation of the Effects of Reference Rate Reform on Financial Reporting (Topic 848). The ASU provides optional expedients and exceptions for applying GAAP to transactions affected by reference rate (e.g., LIBOR) reform if certain criteria are met, for a limited period of time to ease the potential burden in accounting for (or recognizing the effects of) reference rate reform on financial reporting. The ASU is effective as of March 12, 2020 through December 31, 2022. We will evaluate transactions or contract modifications occurring as a result of reference rate reform and determine whether to apply the optional guidance on an ongoing basis. The ASU is currently not expected to have a material impact on our consolidated financial statements. In August 2018, the FASB issued ASU 2018-13, "Fair Value Measurement (Topic 820): Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurements" (ASU 2018-13), which aims to improve the overall usefulness of disclosures to financial statement users and reduce unnecessary costs to companies when preparing fair value measurement disclosures. We adopted this standard effective January 1, 2020 the adoption of ASU 2018-02 did not have a material impact on our consolidated financial statements. In June 2016, the FASB issued ASU 2016-13, "Measurement of Credit Losses on Financial Instruments." ASU 2016-13 replaces the incurred loss approach with an expected loss model for instruments measured at amortized cost and requires entities to record allowances for available-for-sale debt securities rather than reduce the carrying amount as done under the former other-than-temporary impairment model. We adopted ASU 2016-13 as of January 1, 2020 using the cumulative effect transition method. We’ve evaluated our impacted instruments for credit quality indicators, and have determined that there is no cumulative effect transition adjustment to retained earnings as of our adoption date. ASU 2016-13 had an insignificant impact to our condensed consolidated financial statements for the three months ended March 31, 2020 . See also Note 3, Fair Value Measurements, and the section above under the caption “Allowance for Doubtful Accounts.” Recent Accounting Pronouncements to be Adopted In January 2020, the FASB issued ASU 2020-01, Clarifying the Interactions between Topic 321 Investments—Equity Securities, Topic 323 Investments—Equity Method and Joint Ventures, and Topic 815 Derivatives and Hedging. ASU 2020-01 clarifies that a company should consider observable transactions that require a company to either apply or discontinue the equity method of accounting under Topic 323 for the purposes of applying the measurement alternative in accordance with Topic 321 immediately before applying or upon discontinuing the equity method. ASU 2020-01 also clarifies that, when determining the accounting for certain forward contracts and purchased options a company should not consider, whether upon settlement or exercise, if the underlying securities would be accounted for under the equity method or fair value option. ASU 2020-01 is effective for fiscal years beginning after December 15, 2020. Early adoption is permitted, including interim periods for which financial statements have not been issued. We are currently evaluating the effect of ASU 2020-01. In December 2019, the FASB issued ASU 2019-12, "Simplifying the Accounting for Income Taxes," which eliminates certain exceptions within ASC 740, Income Taxes , and clarifies other aspects of the current guidance to promote consistency among reporting entities. ASU 2019-12 is effective for fiscal years beginning after December 15, 2020 and early adoption is permitted in any interim or annual period, with any adjustments reflected as of the beginning of the fiscal year of adoption. We are currently evaluating the effect of adopting this pronouncement on our financial statements and disclosures. In August 2018, the FASB issued ASU 2018-14, "Disclosure Framework - Changes to the Disclosure Requirements for Defined Benefit Plans." ASU 2018-14 eliminates and adds certain disclosures for defined benefit plans. ASU 2018-14 is effective for fiscal years ending after December 15, 2020 using a retrospective approach. Early adoption is permitted. We are currently evaluating the disclosures but do not expect ASU 2018-14 to have a material impact to our disclosures for defined benefit plans.
Revenue from Contract with Customer [Policy Text Block]	Revenue Recognition We recognize revenue from operations through the sale of products, services, and rental of instruments. Revenue from contracts with customers is recognized upon transfer of control of promised products or services to customers in an amount that reflects the consideration we expect to receive in exchange for those products or services. We enter into contracts that can include various combinations of products and services, which are generally accounted for as distinct performance obligations. Revenue is recognized net of any taxes collected from customers (sales tax, value added tax, etc.), which are subsequently remitted to government authorities. Our contracts from customers often include promises to transfer multiple products and services to a customer. Determining whether products and services are considered distinct performance obligations that should be accounted for separately versus together may require significant judgment, and may or may not impact the timing of revenue recognition. Revenue associated with equipment that requires factory installation is not recorded until installation is complete and customer acceptance, if required, has occurred. Certain equipment requires installation due to the fact that the instruments are being operated in a clinical/laboratory environment, and the installation services could result in modification of the equipment in order to ensure that the instruments are working according to specifications of the customer which are subject to validation tests upon completion of the installation. In these arrangements, which require factory installation, the delivery of the equipment and the installation are separate performance obligations. We will recognize the transaction price allocated to the equipment only upon customer acceptance, as the transfer of control has occurred in relation to the equipment at that point in time as the customer has the ability to direct the use of and obtain substantially all of the remaining benefits from the asset. The transaction price allocated to the installation services is also recognized upon completion of the services because without the completion of the installation services and related customer acceptance the customer cannot receive any of the benefits of the service. At the time revenue is recognized, a provision is recognized for estimated product returns as this right is considered variable consideration. Accordingly, when product revenues are recognized, the transaction price is reduced by the estimated amount of product returns. Service revenues on extended warranty contracts are recognized ratably over the life of the service agreement as a stand-ready performance obligation. For arrangements that include a combination of products and services, transaction prices are allocated to performance obligations based on stand-alone selling prices. The method used to determine the stand-alone selling prices for service revenues is based on the observable prices when the services have been sold separately. In those instances where the timing of revenue recognition differs from the timing of invoicing, we have determined that our contracts generally do not include a significant financing component. The primary purpose of our invoicing terms is to provide customers with simple and predictable methods of purchasing our products and services, not to either provide or receive financing to or from our customers. We record contract liabilities when cash payments are received or due in advance of our performance. We do not disclose the value of unsatisfied performance obligations for contracts with an original expected length of one year or less. Our payment terms vary by the type and location of our customer, and the products and services offered. The term between invoicing and when payment is due is not significant. Reagent Rental Agreements Reagent rental agreements are a diagnostic industry sales method that provides use of an instrument and consumables (reagents) to a customer on a per test basis. These agreements may also include maintenance of the underlying instruments retained at customer locations as well as initial training. We initially determine if a reagent rental arrangement contains a lease at lease commencement. Where we have determined that such an arrangement contains a lease, we next must ascertain its lease classification for purposes of applying appropriate accounting treatment as an operating, sales-type or direct financing lease. In addition, for purposes of determining the lease term used in performing the lease classification test, we include the noncancellable period of the lease together with those periods covered by the option to extend the lease if the customer is reasonably certain to exercise that option, the periods covered by an option to terminate the lease if the customer is reasonably certain not to exercise that option, and the periods covered by the option to extend (or not to terminate) the lease in which exercise of the option is controlled by the company. While most of our reagent rental arrangements contain either the option for a lessee to extend and/or cancel, the period in which the contract is enforceable is a very short period and therefore the lease term has been limited to the noncancellable period. Furthermore, it has historically been very rare for these arrangements to contain an option for the lessee to purchase the underlying asset. As discussed in Note 14, Leases, we adopted Accounting Standards Codification (ASC) 842, “Leases,” on a modified retrospective basis effective January 1, 2019 with practical expedients, and did not restate comparative prior periods. We concluded that the use of the instrument (referred to as “lease elements”) is not within the guidance of ASC 606 but rather ASC 842. Accordingly, we first allocate the transaction price between the lease elements and the non-lease elements based on relative standalone selling prices. The determination of the transaction price requires judgment and consideration of any fixed/minimum payments as well as estimates of variable consideration. After allocation, the amount of variable payments allocated to lease components will be recognized as income under ASC 842, while the amount of variable payments allocated to non-lease components will be recognized as income in accordance with ASC 606. Upon our adoption of ASC 842 in 2019, the maintenance services, along with the reagents, are now allocated to the non-lease elements and will be recognized as income in accordance with ASC 606. This change is in alignment with the requirements of ASC 842, and has resulted in a decrease in the amount of rental income and a corresponding increase in the amount of maintenance service revenue that is included in total reported Net sales in our condensed consolidated income statements. Generally, the terms of the arrangements result in the transfer of control on reagents upon either (i) when the consumables are delivered or (ii) when the consumables are consumed by the customer. Historically, our reagent rental arrangements have been predominantly comprised of variable lease payments that fluctuate depending on the volume of reagents purchased, as very few of such arrangements contain any fixed/minimum lease payments. Further, our reagent rental arrangements are predominantly classified as operating leases, and any sales-type leases represent in aggregate a very insignificant amount of lease income. Our reported lease income is primarily variable in nature and is recognized upon delivery or as the reagents are consumed by the customer or delivered. Revenue allocated to the lease elements of these reagent rental arrangements represents approximately 3% of total revenue for both the three months ended March 31, 2020 , and March 31, 2019 , and is included as part of Net sales in our Condensed Consolidated Statements of Income. Contract costs: As a practical expedient, we expense as incurred costs to obtain contracts as the amortization period would have been one year or less. These costs, recorded within Selling, general and administrative expense, include our internal sales force and certain partner sales incentive programs. Disaggregation of Revenue: The following table presents our revenues disaggregated by geographic region based primarily on the location of the use of the product or service (in millions, unaudited): Three Months Ended March 31, 2020 2019 Europe $ 195.7 $ 185.9 Asia 111.4 106.4 United States 229.5 226.1 Other (primarily Canada and Latin America) 35.0 35.6 Total net sales $ 571.6 $ 554.0 The disaggregation of our revenue by industry segment sources is presented in our Segment Information footnote (see Note 11). Deferred revenues represent mostly unrecognized fees billed or collected for extended service arrangements. Deferred revenues are generally recognized ratably over the term of the service contract as our performance obligation is fulfilled over the life of the arrangement. A majority of our deferred revenue balance is classified as current with an expected length of one year or less. The deferred revenue balance at December 31, 2019 and March 31, 2020 was $45.8 million and $50.9 million , respectively.
Accounts Receivable, Allowance for Credit Loss [Table Text Block]	Components of our allowance for doubtful accounts were as follows (in millions): December 31, 2019 $ 20.2 Provision for expected credit losses (0.9 ) Write-offs charged against the allowance (0.5 ) Recoveries collected 0.1 March 31, 2020 $ 18.9

1. Basis of Presentation and_3

1. Basis of Presentation and Use of Estimates Basis of Presentation and Use of Estimates (Tables)	3 Months Ended
	Mar. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Revenue from External Customers by Geographic Areas [Table Text Block]	The following table presents our revenues disaggregated by geographic region based primarily on the location of the use of the product or service (in millions, unaudited): Three Months Ended March 31, 2020 2019 Europe $ 195.7 $ 185.9 Asia 111.4 106.4 United States 229.5 226.1 Other (primarily Canada and Latin America) 35.0 35.6 Total net sales $ 571.6 $ 554.0
Schedule of Product Warranty Liability [Table Text Block]	Warranty liabilities are included in Other current liabilities and Other long-term liabilities in the Condensed Consolidated Balance Sheets. Change in our warranty liability for the three month period ended March 31, 2020 and 2019 were as follows (in millions): Three Months Ended March 31, 2020 2019 Balance at beginning of period $ 9.0 $ 10.1 Provision for warranty 1.9 1.4 Actual warranty costs (2.7 ) (2.2 ) Balance at end of period $ 8.2 $ 9.3
Receivables, Trade and Other Accounts Receivable, Allowance for Doubtful Accounts, Policy [Policy Text Block]	Allowance for Doubtful Accounts In our evaluation of bad debt allowances, we have considered past events, current conditions and reasonable and supportable forecasts about the future. We have considered what, if any, differences in future economic conditions are anticipated from our historical loss experience and based on current economic conditions to result in our required allowance for doubtful accounts as of March 31, 2020 , while reflecting that our account receivable portfolio is heavily current in nature. The adjustments made to historical loss experience reflect current differences in asset-specific risk characteristics, including, for example, accounts receivable by customer type (public or government entity versus private entity) and by geographic location of customer. Components of our allowance for doubtful accounts were as follows (in millions): December 31, 2019 $ 20.2 Provision for expected credit losses (0.9 ) Write-offs charged against the allowance (0.5 ) Recoveries collected 0.1 March 31, 2020 $ 18.9

3. Fair Value Measurements (Ta

3. Fair Value Measurements (Tables)	3 Months Ended
	Mar. 31, 2020
Fair Value Disclosures [Abstract]
Debt Securities, Available-for-sale [Table Text Block]	Available-for-sale investments consist of the following (in millions): March 31, 2020 Amortized Cost Unrealized Gains Unrealized Losses Allowances for Credit Losses Fair Value Short-term investments: Corporate debt securities $ 199.2 $ 0.9 $ (1.7 ) $ — $ 198.4 Municipal obligations 14.3 0.1 — — 14.4 Asset-backed securities 72.2 0.2 (0.7 ) — 71.7 U.S. government sponsored agencies 98.1 2.8 — — 100.9 Foreign government obligations 5.6 — — — 5.6 Other foreign obligations 2.1 — — — 2.1 391.5 4.0 (2.4 ) — 393.1 Long-term investments: Asset-backed securities 0.1 — — — 0.1 0.1 — — — 0.1 Total $ 391.6 $ 4.0 $ (2.4 ) $ — $ 393.2
Schedule of financial assets and liabilities carried at fair value on a recurring basis	Financial assets and liabilities carried at fair value and measured on a recurring basis as of March 31, 2020 are classified in the hierarchy as follows (in millions): Level 1 Level 2 Level 3 Total Financial assets carried at fair value: Cash equivalents: Commercial paper $ — $ 65.5 $ — $ 65.5 Asset-backed securities — 0.1 — 0.1 Time deposits 26.4 10.0 — 36.4 Money market funds 96.5 — — 96.5 Total cash equivalents (a) 122.9 75.6 — 198.5 Restricted investment 5.6 — — 5.6 Equity securities (b) 5,448.4 — — 5,448.4 Available-for-sale investments: Corporate debt securities — 198.4 — 198.4 U.S. government sponsored agencies — 100.9 — 100.9 Foreign government obligations — 5.6 — 5.6 Other foreign obligations — 2.1 — 2.1 Municipal obligations — 14.4 — 14.4 Asset-backed securities — 71.8 — 71.8 Total available-for-sale investments (c) — 393.2 — 393.2 Forward foreign exchange contracts (d) — 0.7 — 0.7 Total financial assets carried at fair value $ 5,576.9 $ 469.5 $ — $ 6,046.4 Financial liabilities carried at fair value: Forward foreign exchange contracts (e) $ — $ 1.3 $ — $ 1.3 Contingent consideration (f) — — 3.5 3.5 Total financial liabilities carried at fair value $ — $ 1.3 $ 3.5 $ 4.8 Financial assets and liabilities carried at fair value and measured on a recurring basis as of December 31, 2019 are classified in the hierarchy as follows (in millions): Level 1 Level 2 Level 3 Total Financial assets carried at fair value: Cash equivalents: Commercial paper $ — $ 42.9 $ — $ 42.9 Time deposits 31.2 10.0 — 41.2 Asset-backed securities — 0.1 — 0.1 Money market funds 69.9 — — 69.9 Total cash equivalents (a) 101.1 53.0 — 154.1 Restricted investment 5.6 — — 5.6 Equity securities (b) 4,664.4 — — 4,664.4 Available-for-sale investments: Corporate debt securities — 204.5 — 204.5 U.S. government sponsored agencies — 106.1 — 106.1 Foreign government obligations — 4.7 — 4.7 Other foreign obligations — 3.1 — 3.1 Municipal obligations — 11.6 — 11.6 Asset-backed securities — 72.9 — 72.9 Total available-for-sale investments (c) — 402.9 — 402.9 Forward foreign exchange contracts (d) — 0.9 — 0.9 Total financial assets carried at fair value $ 4,771.1 $ 456.8 $ — $ 5,227.9 Financial liabilities carried at fair value: Forward foreign exchange contracts (e) $ — $ 1.0 $ — $ 1.0 Contingent consideration (f) — — 4.9 4.9 Total financial liabilities carried at fair value $ — $ 1.0 $ 4.9 $ 5.9 (a) Cash equivalents are included in Cash and cash equivalents in the Condensed Consolidated Balance Sheets. (b) Equity securities are included in the following accounts in the Condensed Consolidated Balance Sheets (in millions): March 31, 2020 December 31, 2019 Short-term investments $ 40.1 $ 51.0 Other investments 5,408.3 4,613.4 Total $ 5,448.4 $ 4,664.4 The year-to-date unrealized gains on our equity securities as of March 31, 2020 were $827.7 million and were primarily due to our investment in Sartorius AG and are recorded in our Condensed Consolidated Statements of Income. We own shares of ordinary voting stock of Sartorius AG (Sartorius), of Goettingen, Germany, a process technology supplier to the biotechnology, pharmaceutical, chemical and food and beverage industries. We own over 37% of the outstanding voting shares (excluding treasury shares) of Sartorius as of March 31, 2020 . The Sartorius family trust and Sartorius family members hold a controlling interest of the outstanding voting shares. We do not have any representative or designee on Sartorius' board of directors, nor do we have the ability to exercise significant influence over the operating and financial policies of Sartorius. (c) Available-for-sale investments are included in the following accounts in the Condensed Consolidated Balance Sheets (in millions): March 31, 2020 December 31, 2019 Short-term investments $ 393.1 $ 402.8 Other investments 0.1 0.1 Total $ 393.2 $ 402.9 (d) Forward foreign exchange contracts in an asset position are included in Other current assets in the Condensed Consolidated Balance Sheets. (e) Forward foreign exchange contracts in a liability position are included in Other current liabilities in the Condensed Consolidated Balance Sheets. (f) Contingent consideration liability is included in the following accounts in the Condensed Consolidated Balance Sheets (in millions): March 31, 2020 December 31, 2019 Other current liabilities $ 3.5 $ 3.3 Other long-term liabilities — 1.6 Total $ 3.5 $ 4.9
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	The following table provides a reconciliation of the Level 3 contingent consideration liabilities measured at estimated fair value (in millions): December 31, 2019 $ 4.9 Analytical flow cytometer platform: Payment of sales milestone (1.3 ) Decrease in estimated fair value of contingent consideration included in Selling, general and administrative expense (0.1 ) Foreign distributor earn-outs: Change in estimated fair value of contingent consideration included in Selling, general and administrative expense — March 31, 2020 $ 3.5
Schedule of available-for-sale investments	Available-for-sale investments consist of the following (in millions): December 31, 2019 Amortized Cost Unrealized Gains Unrealized Losses Estimated Fair Value Short-term investments: Corporate debt securities $ 203.2 $ 1.4 $ (0.1 ) $ 204.5 Municipal obligations 11.5 0.1 — 11.6 Asset-backed securities 72.7 0.2 (0.1 ) 72.8 U.S. government sponsored agencies 105.6 0.7 (0.2 ) 106.1 Foreign government obligations 4.7 — — 4.7 Other foreign obligations 3.1 — — 3.1 400.8 2.4 (0.4 ) 402.8 Long-term investments: Asset-backed securities 0.1 — — 0.1 0.1 — — 0.1 Total $ 400.9 $ 2.4 $ (0.4 ) $ 402.9
Summary of fair value of gross unrealized losses for investments with unrealized losses	The following is a summary of investments with gross unrealized losses and the associated fair value (in millions): March 31, 2020 Less than 12 months Greater than 12 months Total Description of securities: Fair Value Unrealized Losses Fair Value Unrealized Losses Fair Value Unrealized Losses Corporate debt securities $ 106.0 $ 1.7 $ — $ — $ 106.0 $ 1.7 Asset-backed securities 55.2 0.6 3.7 0.1 58.9 0.7 Total $ 161.2 $ 2.3 $ 3.7 $ 0.1 $ 164.9 $ 2.4 December 31, 2019 Less than 12 months Greater than 12 months Total Description of securities: Fair Value Unrealized Losses Fair Value Unrealized Losses Fair Value Unrealized Losses Corporate debt securities $ 46.5 $ 0.1 $ 2.1 $ — $ 48.6 $ 0.1 Asset-backed securities 17.9 — 7.0 0.1 24.9 0.1 U.S government sponsored agencies 27.5 0.2 10.8 — 38.3 0.2 Total $ 91.9 $ 0.3 $ 19.9 $ 0.1 $ 111.8 $ 0.4
Discussion of current derivative risk management	The following is a summary of our forward foreign exchange contracts (in millions): March 31, 2020 Contracts maturing in April through June 2020 to sell foreign currency: Notional value $ 58.6 Unrealized gain $ 0.2 Contracts maturing in April through June 2020 to purchase foreign currency: Notional value $ 237.1 Unrealized loss $ (0.9 )
Summary of amortized cost and estimated fair value of debt securities by contractual maturity date	The following is a summary of the amortized cost and estimated fair value of our debt securities at March 31, 2020 by contractual maturity date (in millions): Amortized Cost Estimated Fair Value Mature in less than one year $ 163.8 $ 163.9 Mature in one to five years 167.3 167.6 Mature in more than five years 60.5 61.7 Total $ 391.6 $ 393.2
Estimated fair value of financial instruments	The estimated fair value of our long-term debt discussed above and the level of the fair value hierarchy within which the fair value measurement is categorized are as follows (in millions): March 31, 2020 December 31, 2019 Carrying Amount Estimated Fair Value Fair Value Hierarchy Level Carrying Amount Estimated Fair Value Fair Value Hierarchy Level Total current maturities long-term debt, excluding leases $ 424.5 $ 422.9 2 $ 424.4 $ 435.5 2

4. Intangible Assets, Goodwi_2

4. Intangible Assets, Goodwill and Other (Tables)	3 Months Ended
	Mar. 31, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
Changes to goodwill by segment	Changes to goodwill by segment were as follows (in millions): Life Science Clinical Diagnostics Total Balances as of December 31, 2019: Goodwill $ 250.1 $ 349.2 $ 599.3 Accumulated impairment losses (41.8 ) (293.4 ) (335.2 ) Goodwill, net 208.3 55.8 264.1 Acquisitions — — — Balances as of March 31, 2020: Goodwill 250.1 349.2 599.3 Accumulated impairment losses (41.8 ) (293.4 ) (335.2 ) Goodwill, net $ 208.3 $ 55.8 $ 264.1 In conjunction with the purchase of all the issued and outstanding shares of a foreign distributor in October 2019 (see Note 2, "Acquisitions"), we recorded $3.4 million of Customer relationships, a definite-lived intangible assets.
Schedule of identifiable purchased intangible assets with definite lives	Information regarding our identifiable purchased intangible assets with definite and indefinite lives is as follows (in millions): March 31, 2020 Weighted-Average Remaining Amortization Period (years) Purchase Price Accumulated Amortization Net Carrying Amount Customer relationships/lists 6.26 $ 105.1 $ (74.5 ) $ 30.6 Know how 5.48 187.0 (162.4 ) 24.6 Developed product technology 8.14 142.1 (94.4 ) 47.7 Licenses 8.51 76.0 (45.2 ) 30.8 Tradenames 8.34 6.4 (3.7 ) 2.7 Covenants not to compete 5.76 3.1 (1.4 ) 1.7 Other — 0.1 (0.1 ) — Total definite-lived intangible assets 519.8 (381.7 ) 138.1 In-process research and development 0.2 — 0.2 Total purchased intangible assets $ 520.0 $ (381.7 ) $ 138.3 December 31, 2019 Weighted-Average Remaining Amortization Period (years) Purchase Price Accumulated Amortization Net Carrying Amount Customer relationships/lists 6.36 $ 107.2 $ (74.3 ) $ 32.9 Know how 5.71 188.5 (162.6 ) 25.9 Developed product technology 8.31 144.2 (93.9 ) 50.3 Licenses 8.74 76.0 (44.4 ) 31.6 Tradenames 8.50 6.4 (3.6 ) 2.8 Covenants not to compete 6.01 3.2 (1.4 ) 1.8 Other — 0.1 (0.1 ) — Total definite-lived intangible assets 525.6 (380.3 ) 145.3 In-process research and development 0.2 — 0.2 Total purchased intangible assets $ 525.8 $ (380.3 ) $ 145.5
Finite-lived Intangible Assets Amortization Expense [Table Text Block]	Amortization expense related to purchased intangible assets is as follows (in millions): Three Months Ended March 31, 2020 2019 Amortization expense $ 5.9 $ 5.5

5. Supplemental Cash Flow In_2

5. Supplemental Cash Flow Information Cash Flow, Supplemental Disclosure (Tables)	3 Months Ended
	Mar. 31, 2020
Supplemental Cash Flow Elements [Abstract]
Cash Flow, Supplemental Disclosures [Text Block]	SUPPLEMENTAL CASH FLOW INFORMATION The reconciliation of net income to net cash provided by operating activities is as follows (in millions): Three Months Ended March 31, 2020 March 31, 2019 Net income $ 685.9 $ 865.2 Adjustments to reconcile net income to net cash provided by operating activities: Depreciation and amortization 33.6 32.9 Reduction in the carrying amount of right-of-use assets 9.6 10.0 Share-based compensation 9.7 8.5 Gains on dispositions of securities (0.4 ) — Other-than-temporary impairment losses on investment — 1.6 Changes in fair market value of equity securities (827.7 ) (1,059.2 ) Losses on dispositions of fixed assets 0.1 0.3 Changes in fair value of contingent consideration (0.1 ) (0.5 ) Payments for operating lease liabilities (9.3 ) (11.7 ) Decrease (increase) in accounts receivable 2.2 (2.0 ) Increase in inventories (13.7 ) (11.6 ) Increase in other current assets (9.5 ) (16.7 ) (Decrease) increase in accounts payable and other current liabilities (25.6 ) 20.6 Increase in income taxes payable 20.9 13.8 Increase in deferred income taxes 171.8 238.5 Increase (decrease) in other long term liabilities 15.7 (38.3 ) Other (0.4 ) (8.5 ) Net cash provided by operating activities $ 62.8 $ 42.9 Non-cash investing activities: Purchased property, plant and equipment $ 6.0 $ 5.1 Purchased marketable securities and investments $ 2.7 $ —
Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]	The reconciliation of net income to net cash provided by operating activities is as follows (in millions): Three Months Ended March 31, 2020 March 31, 2019 Net income $ 685.9 $ 865.2 Adjustments to reconcile net income to net cash provided by operating activities: Depreciation and amortization 33.6 32.9 Reduction in the carrying amount of right-of-use assets 9.6 10.0 Share-based compensation 9.7 8.5 Gains on dispositions of securities (0.4 ) — Other-than-temporary impairment losses on investment — 1.6 Changes in fair market value of equity securities (827.7 ) (1,059.2 ) Losses on dispositions of fixed assets 0.1 0.3 Changes in fair value of contingent consideration (0.1 ) (0.5 ) Payments for operating lease liabilities (9.3 ) (11.7 ) Decrease (increase) in accounts receivable 2.2 (2.0 ) Increase in inventories (13.7 ) (11.6 ) Increase in other current assets (9.5 ) (16.7 ) (Decrease) increase in accounts payable and other current liabilities (25.6 ) 20.6 Increase in income taxes payable 20.9 13.8 Increase in deferred income taxes 171.8 238.5 Increase (decrease) in other long term liabilities 15.7 (38.3 ) Other (0.4 ) (8.5 ) Net cash provided by operating activities $ 62.8 $ 42.9 Non-cash investing activities: Purchased property, plant and equipment $ 6.0 $ 5.1 Purchased marketable securities and investments $ 2.7 $ —

6. Long-Term Debt (Tables)

6. Long-Term Debt (Tables)	3 Months Ended
	Mar. 31, 2020
Debt Disclosure [Abstract]
Schedule of Long-term Debt Instruments [Table Text Block]	The principal components of long-term debt are as follows (in millions): March 31, December 31, 4.875% Senior Notes due 2020 principal amount $ 425.0 $ 425.0 Less unamortized discount and debt issuance costs (0.5 ) (0.6 ) 4.875% Senior Notes less unamortized discount and debt issuance costs 424.5 424.4 Finance leases and other debt 14.0 15.4 438.5 439.8 Less current maturities (426.3 ) (426.2 ) Long-term debt $ 12.2 $ 13.6

7. Accumulated Other Compreh_2

7. Accumulated Other Comprehensive Income 7. Accumulated Other Comprehensive Income (Tables)	3 Months Ended
	Mar. 31, 2020
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]	Accumulated other comprehensive income included in our Condensed Consolidated Balance Sheets consists of the following components (in millions): Foreign currency translation adjustments Foreign other post-employment benefits adjustments Net unrealized holding gains on available-for-sale investments Total accumulated other comprehensive income (loss) Balances as of January 1, 2020: $ (72.4 ) $ (22.2 ) $ 7.2 $ (87.4 ) Other comprehensive (loss) income, before reclassifications (62.9 ) 0.2 — (62.7 ) Amounts reclassified from Accumulated other comprehensive income — 0.3 (0.4 ) (0.1 ) Income tax effects 0.9 0.2 0.1 1.2 Other comprehensive (loss) income, net of income taxes (62.0 ) 0.7 (0.3 ) (61.6 ) Balances as of March 31, 2020: $ (134.4 ) $ (21.5 ) $ 6.9 $ (149.0 ) Foreign currency translation adjustments Foreign other post-employment benefits adjustments Net unrealized holding gains on available-for-sale investments Total accumulated other comprehensive income (loss) Balances as of January 1, 2019: $ (35.5 ) $ (14.8 ) $ 3.3 $ (47.0 ) Other comprehensive (loss) income, before reclassifications (36.4 ) 0.2 2.0 (34.2 ) Amounts reclassified from Accumulated other comprehensive income — 0.2 — 0.2 Income tax effects — — — — Other comprehensive (loss) income, net of income taxes (36.4 ) 0.4 2.0 (34.0 ) Balances as of March 31, 2019: $ (71.9 ) $ (14.4 ) $ 5.3 $ (81.0 )
Reclassification Out of Accumulated Other Comprehensive Income [Table Text Block]	The impact to income before taxes for amounts reclassified out of Accumulated other comprehensive income into the Condensed Consolidated Statements of Income, with presentation location, were as follows (in millions): Three Months Ended March 31, Components of Comprehensive income 2020 2019 Location Amortization of foreign other post-employment benefit items $ (0.3 ) $ (0.2 ) Other (income) expense, net Net holding gains on equity securities and available-for-sale investments $ 0.4 $ — Other (income) expense, net

8. Earnings Per Share (Tables)

8. Earnings Per Share (Tables)	3 Months Ended
	Mar. 31, 2020
Earnings Per Share [Abstract]
Schedule of weighted-average common shares outstanding used to calculate basic and diluted earnings per shares and the anti-dilutive shares	The weighted average number of common shares outstanding used to calculate basic and diluted earnings per share, and the anti-dilutive shares that are excluded from the diluted earnings per share calculation are as follows (in thousands): Three Months Ended March 31, 2020 2019 Basic weighted average shares outstanding 29,865 29,801 Effect of potentially dilutive stock options and restricted stock awards 331 303 Diluted weighted average common shares 30,196 30,104 Anti-dilutive shares 62 226

9. Other Income and Expenses (

9. Other Income and Expenses (Tables)	3 Months Ended
	Mar. 31, 2020
Other Income and Expenses [Abstract]
Schedule of other income (expense), net	Other (income) expense, net includes the following components (in millions): Three Months Ended March 31, 2020 2019 Interest and investment income $ (2.8 ) $ (19.5 ) Net realized gain on investments (0.4 ) — Other-than-temporary impairment loss on investment — 1.6 Other (income) expense (0.1 ) (0.8 ) Other (income) expense, net $ (3.3 ) $ (18.7 )

11. Segment Information Segm_2

11. Segment Information Segment Reporting (Tables)	3 Months Ended
	Mar. 31, 2020
Segment Reporting [Abstract]
Schedule of Segment Reporting Information, by Segment [Table Text Block]	Information regarding industry segments for the three months ended March 31, 2020 and 2019 is as follows (in millions): Life Science Clinical Diagnostics Other Operations Segment net sales 2020 $ 227.2 $ 340.3 $ 4.1 2019 $ 215.7 $ 334.1 $ 4.2 Segment net profit (loss) 2020 $ 25.4 $ 46.2 $ 0.7 2019 $ 22.8 $ 30.9 $ (0.1 )
Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]	The following reconciles total segment profit to consolidated income before income taxes (in millions): Three Months Ended March 31, 2020 2019 Total segment profit $ 72.3 $ 53.6 Foreign currency exchange losses, net (0.9 ) (1.3 ) Net corporate operating, interest and other expense not allocated to segments (3.7 ) (2.9 ) Change in fair market value of equity securities 827.7 1,059.2 Other income (expense), net 3.3 18.7 Consolidated income before income taxes $ 898.7 $ 1,127.3

13. Restructuring Costs (Tables

13. Restructuring Costs (Tables)	3 Months Ended
	Mar. 31, 2020
Restructuring Cost and Reserve [Line Items]
Restructuring and Related Costs [Table Text Block]	The following table summarizes the activity of our European and North American reorganization restructuring reserves for severance (in millions): Life Science Clinical Diagnostics Total Balances as of December 31, 2019: $ 6.2 $ 19.1 $ 25.3 Adjustment to expense (0.3 ) (2.1 ) (2.4 ) Cash payments (2.9 ) (5.7 ) (8.6 ) Foreign currency translation gains (0.1 ) (0.2 ) (0.3 ) Balances as of March 31, 2020: $ 2.9 $ 11.1 $ 14.0 The following table summarizes the activity for the facility closure restructuring reserves for severance and exit costs (in millions): Balances as of December 31, 2019: $ 3.2 Cash payments (0.3 ) Balances as of March 31, 2020: $ 2.9

14. Leases (Tables)

14. Leases (Tables)	3 Months Ended
	Mar. 31, 2020
14. Leases [Abstract]
Lease, Cost [Table Text Block]	The components of lease expense were as follows (in millions): Three Months Ended Three Months Ended March 31, March 31, 2020 2019 Operating lease cost $ 12.6 $ 12.4 Finance lease cost: Amortization of right-of-use assets $ 0.1 $ 0.1 Interest on lease liabilities 0.2 0.2 Total finance lease cost $ 0.3 $ 0.3 Sublease income $ 0.7 $ 0.7 The sublease is for a building with a term that ends in 2025, with no options to extend or renew.
Maturities Of Lease Liabilities For Operating and Finance Leases [Table Text Block]	Maturities of lease liabilities were as follows (in millions): Year Ending December 31, Operating Leases Finance Leases 2020 (excluding the three months ended March 31, 2020) $ 32.0 $ 1.2 2021 37.7 1.2 2022 30.5 1.1 2023 25.7 1.1 2024 23.0 1.1 Thereafter 105.0 14.9 Total lease payments 253.9 20.6 Less imputed interest (44.0 ) (9.1 ) Total $ 209.9 $ 11.5
Lessee Supplemental Cash Flow Information [Table Text Block]	Supplemental cash flow information related to leases was as follows (in millions): Three Months Ended Three Months Ended March 31, March 31, 2020 2019 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 11.4 $ 11.7 Operating cash flows from finance leases $ 0.2 $ 0.2 Financing cash flows from finance leases $ 0.1 $ 0.2 Right-of-use assets obtained in exchange for lease obligations: Operating leases $ 10.8 $ 1.4 Finance leases $ — $ —
Lessee Supplemental Balance Sheet Information [Table Text Block]	Supplemental balance sheet information related to leases was as follows (in millions): March 31, 2020 December 31, 2019 Operating Leases Operating lease right-of-use assets $ 200.5 $ 201.9 Current operating lease liabilities $ 34.4 $ 35.4 Operating lease liabilities 175.5 176.0 Total operating lease liabilities $ 209.9 $ 211.4 Finance leases are included in Property, plant and equipment, Current maturities of long-term debt, and Long-term debt, net of current maturities. March 31, 2020 December 31, 2019 Finance Leases Property, plant and equipment, gross $ 11.4 $ 11.4 Less: accumulated depreciation and amortization (4.3 ) (4.2 ) Property, plant and equipment, net $ 7.1 $ 7.2 Current maturities of long-term debt and notes payable $ 0.5 $ 0.5 Long-term debt, net of current maturities 11.0 11.2 Total finance lease liabilities $ 11.5 $ 11.7 March 31, 2020 December 31, 2019 Weighted Average Remaining Lease Term Operating leases - in years 9 9 Finance leases - in years 18 18 Weighted Average Discount Rate Operating leases 4.1 % 4.2 % Finance leases 6.5 % 6.5 %

1. Basis of Presentation and_4

1. Basis of Presentation and Use of Estimates Organization, Consolidation and Presentation of Financial Statements (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Dec. 31, 2019	Dec. 31, 2018
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Net sales	$ 571,644	$ 553,979
Cost of goods sold	254,276	242,217
Deferred Revenue	50,900		$ 45,800
Retained earnings	6,156,691		5,470,779
Accumulated other comprehensive loss	(148,955)		(87,348)
Total stockholders' equity	$ 6,293,079	$ 4,863,855	5,755,057	$ 4,020,331
Revenue Allocation Percent To Lease Elements	3.00%	3.00%
Additional paid-in-capital	$ 423,742		$ 410,020
Selling, general and administrative expense	193,692	$ 207,581
Research and Development Expense	49,303	47,575
Interest expense	5,690	5,986
Other Nonoperating Income (Expense)	3,273	18,696
Europe [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Net sales	195,700	185,900
Asia Pacific [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Net sales	111,400	106,400
UNITED STATES
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Net sales	229,500	226,100
Americas [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Net sales	$ 35,000	$ 35,600

1. Basis of Presentation and_5

1. Basis of Presentation and Use of Estimates Warranty Rollforward (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Warranty accrual, beginning of period	$ 9	$ 10.1
Provision for warranty	1.9	1.4
Actual warranty costs	(2.7)	(2.2)
Warranty accrual, end of period	$ 8.2	$ 9.3

1. Basis of Presentation and_6

1. Basis of Presentation and Use of Estimates Capitalized Cloud Computing Arrangements (Details) - USD ($) $ in Millions	Mar. 31, 2020	Dec. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Capitalized Cloud Computing Arrangements	$ 3.9	$ 3.1

1. Basis of Presentation and_7

1. Basis of Presentation and Use of Estimates Accounts Receivables Allowance for Credit Loss (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2020	Dec. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Accounts Receivable, Allowance for Credit Loss	$ 18.9	$ 20.2
Accounts Receivable, Allowance for Credit Loss, Period Increase (Decrease)	(0.9)
Allowance for Loan and Lease Losses, Write-offs	(0.5)
Accounts Receivable, Allowance for Credit Loss, Recovery	$ 0.1

2. Acquisitions (Details)

2. Acquisitions (Details) - USD ($) $ in Millions	3 Months Ended
	Dec. 31, 2019	Oct. 01, 2019
Business Combinations [Abstract]
Business Combination, Consideration Transferred	$ 4.2
Payments to Acquire Businesses, Net of Cash Acquired	3.6
Business Combination, Contingent Consideration, Liability		$ 0.6
Business Combination, Separately Recognized Transactions, Revenues and Gains Recognized	0.4
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles		3.4
Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Assets	0.2
Business Combination, Consideration Transferred, Liabilities Incurred	$ 0.8
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net		$ 1.4

3. Fair Value Measurements Fai

3. Fair Value Measurements Fair Value Level Table (Details) - USD ($) $ in Millions		3 Months Ended
		Mar. 31, 2020	Dec. 31, 2019	Oct. 01, 2019
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Unrealized Gain on Securities		$ 827.7
Debt Securities, Available-for-sale		393.2
Business Combination, Contingent Consideration, Liability				$ 0.6
Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Restricted Investments, at Fair Value		5.6	$ 5.6
Equity Securities	[1]	5,448.4	4,664.4
Debt Securities, Available-for-sale	[2]	393.2	402.9
Forward Foreign Exchange Contracts, Asset, Fair Value Disclosure	[3]	0.7	0.9
Assets, Fair Value Disclosure		6,046.4	5,227.9
Forward Foreign Exchange Contracts, Liability, Fair Value Disclosure	[4]	1.3	1
Business Combination, Contingent Consideration, Liability	[5]	3.5	4.9
Liabilities, Fair Value Disclosure		4.8	5.9
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Restricted Investments, at Fair Value		5.6	5.6
Equity Securities	[1]	5,448.4	4,664.4
Debt Securities, Available-for-sale	[2]	0	0
Forward Foreign Exchange Contracts, Asset, Fair Value Disclosure	[3]	0	0
Assets, Fair Value Disclosure		5,576.9	4,771.1
Forward Foreign Exchange Contracts, Liability, Fair Value Disclosure	[4]	0	0
Business Combination, Contingent Consideration, Liability	[5]	0	0
Liabilities, Fair Value Disclosure		0	0
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Restricted Investments, at Fair Value		0	0
Equity Securities	[1]	0	0
Debt Securities, Available-for-sale	[2]	393.2	402.9
Forward Foreign Exchange Contracts, Asset, Fair Value Disclosure	[3]	0.7	0.9
Assets, Fair Value Disclosure		469.5	456.8
Forward Foreign Exchange Contracts, Liability, Fair Value Disclosure	[4]	1.3	1
Business Combination, Contingent Consideration, Liability	[5]	0	0
Liabilities, Fair Value Disclosure		1.3	1
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Restricted Investments, at Fair Value		0	0
Equity Securities	[1]	0	0
Debt Securities, Available-for-sale	[2]	0	0
Forward Foreign Exchange Contracts, Asset, Fair Value Disclosure	[3]	0	0
Assets, Fair Value Disclosure		0	0
Forward Foreign Exchange Contracts, Liability, Fair Value Disclosure	[4]	0	0
Business Combination, Contingent Consideration, Liability	[5]	3.5	4.9
Liabilities, Fair Value Disclosure		3.5	4.9
Asset-backed Securities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	[6]	0.1	0.1
Asset-backed Securities [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	[6]	0	0
Asset-backed Securities [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	[6]	0.1	0.1
Asset-backed Securities [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	[6]	0	0
Commercial Paper [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	[6]	65.5	42.9
Commercial Paper [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	[6]	0	0
Commercial Paper [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	[6]	65.5	42.9
Commercial Paper [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	[6]	0	0
Time Deposits [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	[6]	36.4	41.2
Time Deposits [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	[6]	26.4	31.2
Time Deposits [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	[6]	10	10
Time Deposits [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	[6]	0	0
Money Market Funds [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	[6]	96.5	69.9
Money Market Funds [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	[6]	96.5	69.9
Money Market Funds [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	[6]	0	0
Money Market Funds [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	[6]	0	0
Cash Equivalents [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	[6]	198.5	154.1
Cash Equivalents [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	[6]	122.9	101.1
Cash Equivalents [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	[6]	75.6	53
Cash Equivalents [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	[6]	0	0
Foreign Government Debt [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	[2]	2.1
Foreign Government Debt [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	[2]	0
Foreign Government Debt [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	[2]	2.1
Foreign Government Debt [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	[2]	0
Municipal Obligations (Member) | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	[2]	14.4	11.6
Municipal Obligations (Member) | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	[2]	0	0
Municipal Obligations (Member) | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	[2]	14.4	11.6
Municipal Obligations (Member) | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	[2]	0	0
Foreign Government Obligations [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	[2]	5.6	4.7
Foreign Government Obligations [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	[2]	0	0
Foreign Government Obligations [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	[2]	5.6	4.7
Foreign Government Obligations [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	[2]	0	0
Corporate Debt Securities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	[2]	198.4	204.5
Corporate Debt Securities [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	[2]	0	0
Corporate Debt Securities [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	[2]	198.4	204.5
Corporate Debt Securities [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	[2]	0	0
US Government Sponsored Agencies [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	[2]	100.9	106.1
US Government Sponsored Agencies [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	[2]	0	0
US Government Sponsored Agencies [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	[2]	100.9	106.1
US Government Sponsored Agencies [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	[2]	0	0
Asset-backed Securities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	[2]	71.8	72.9
Asset-backed Securities [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	[2]	0	0
Asset-backed Securities [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	[2]	71.8	72.9
Asset-backed Securities [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	[2]	0	0
Other Current Liabilities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business Combination, Contingent Consideration, Liability	[5]	3.5	3.3
Other Noncurrent Liabilities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business Combination, Contingent Consideration, Liability	[5]	0	1.6
Short-term Investments [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equity Securities	[1]	40.1	51
Debt Securities, Available-for-sale	[2]	393.1	402.8
Short-term Investments [Member] | Foreign Government Debt [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale		2.1	3.1
Short-term Investments [Member] | Municipal Obligations (Member) | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale		14.4	11.6
Short-term Investments [Member] | Foreign Government Obligations [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale		5.6	4.7
Short-term Investments [Member] | Corporate Debt Securities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale		198.4	204.5
Short-term Investments [Member] | US Government Sponsored Agencies [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale		100.9	106.1
Short-term Investments [Member] | Asset-backed Securities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale		71.7	72.8
Other Investments [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equity Securities	[1]	5,408.3	4,613.4
Debt Securities, Available-for-sale	[2]	0.1	$ 0.1
Analytical Flow Cytometer Platform [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business Combination, Contingent Consideration, Liability		2.9
Sales milestone minimum amount [Member] | Analytical Flow Cytometer Platform [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, Low		$ 0
[1]	Equity securities are included in the following accounts in the Condensed Consolidated Balance Sheets (in millions): March 31, 2020 December 31, 2019 Short-term investments $ 40.1 $ 51.0 Other investments 5,408.3 4,613.4 Total $ 5,448.4 $ 4,664.4
[2]	Available-for-sale investments are included in the following accounts in the Condensed Consolidated Balance Sheets (in millions): March 31, 2020 December 31, 2019 Short-term investments $ 393.1 $ 402.8 Other investments 0.1 0.1 Total $ 393.2 $ 402.9
[3]	Forward foreign exchange contracts in an asset position are included in Other current assets in the Condensed Consolidated Balance Sheets.
[4]	Forward foreign exchange contracts in a liability position are included in Other current liabilities in the Condensed Consolidated Balance Sheets.
[5]	Contingent consideration liability is included in the following accounts in the Condensed Consolidated Balance Sheets (in millions): March 31, 2020 December 31, 2019 Other current liabilities $ 3.5 $ 3.3 Other long-term liabilities — 1.6 Total $ 3.5 $ 4.9
[6]	Cash equivalents are included in Cash and cash equivalents in the Condensed Consolidated Balance Sheets.

3. Fair Value Measurements 3.

3. Fair Value Measurements 3. Contingent Consideration (Details) - USD ($) $ in Millions		3 Months Ended		28 Months Ended
		Mar. 31, 2020	Dec. 31, 2019	Mar. 31, 2019	Oct. 01, 2019
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value		$ 3.5	$ 4.9
Business Combination, Contingent Consideration, Liability					$ 0.6
Analytical Flow Cytometer Platform [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent consideration milestone payments		(1.3)
Business Combination, Contingent Consideration, Liability		2.9
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances		(0.1)		$ (13.9)
Distributor [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent consideration milestone payments		(1.4)	(0.7)
Business Combination, Contingent Consideration, Liability		0.6
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances		$ 0
Sales milestone percentage of annual invoices [Member] | Analytical Flow Cytometer Platform [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business Acquisition, Contingent Consideration, Potential Percentage Payout		39.00%
Sales milestone percentage of annual invoices low [Member] | Analytical Flow Cytometer Platform [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business Acquisition, Contingent Consideration, Potential Percentage Payout		20.00%
Sales milestone minimum amount [Member] | Analytical Flow Cytometer Platform [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, Low		$ 0
Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business Combination, Contingent Consideration, Liability	[1]	3.5	4.9
Other Noncurrent Liabilities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business Combination, Contingent Consideration, Liability	[1]	0	1.6
Other Current Liabilities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business Combination, Contingent Consideration, Liability	[1]	$ 3.5	$ 3.3
[1]	Contingent consideration liability is included in the following accounts in the Condensed Consolidated Balance Sheets (in millions): March 31, 2020 December 31, 2019 Other current liabilities $ 3.5 $ 3.3 Other long-term liabilities — 1.6 Total $ 3.5 $ 4.9

3. Foreign Exchange Forward Co

3. Foreign Exchange Forward Contracts (Details) $ in Millions	3 Months Ended
	Mar. 31, 2020USD ($)
Forward foreign exchange contract to sell foreign currency [Member]
Derivatives, Fair Value [Line Items]
Derivative, Notional Amount	$ 58.6
Gain (Loss) on Foreign Currency Derivative Instruments not Designated as Hedging Instruments	0.2
Forward foreign exchange contract to purchase foreign currency [Member]
Derivatives, Fair Value [Line Items]
Derivative, Notional Amount	237.1
Gain (Loss) on Foreign Currency Derivative Instruments not Designated as Hedging Instruments	$ (0.9)

3. Available-for-Sale Investme

3. Available-for-Sale Investments (Details) - USD ($) $ in Millions		Mar. 31, 2020	Dec. 31, 2019
Debt Securities, Available-for-sale [Line Items]
Amortized Cost		$ 391.6
Debt Securities, Available-for-sale		393.2
Fair Value, Recurring [Member]
Debt Securities, Available-for-sale [Line Items]
Debt Securities, Available-for-sale	[1]	393.2	$ 402.9
Fair Value, Recurring [Member] | Corporate Debt Securities [Member]
Debt Securities, Available-for-sale [Line Items]
Debt Securities, Available-for-sale	[1]	198.4	204.5
Fair Value, Recurring [Member] | Municipal obligations [Member]
Debt Securities, Available-for-sale [Line Items]
Debt Securities, Available-for-sale	[1]	14.4	11.6
Fair Value, Recurring [Member] | US Government Sponsored Agencies [Member]
Debt Securities, Available-for-sale [Line Items]
Debt Securities, Available-for-sale	[1]	100.9	106.1
Fair Value, Recurring [Member] | Foreign Government Obligations [Member]
Debt Securities, Available-for-sale [Line Items]
Debt Securities, Available-for-sale	[1]	5.6	4.7
Fair Value, Recurring [Member] | Foreign Government Debt [Member]
Debt Securities, Available-for-sale [Line Items]
Debt Securities, Available-for-sale	[1]	2.1
Fair Value, Recurring [Member] | Asset-backed Securities [Member]
Debt Securities, Available-for-sale [Line Items]
Debt Securities, Available-for-sale	[1]	71.8	72.9
Fair Value, Recurring [Member] | Debt Securities [Member]
Debt Securities, Available-for-sale [Line Items]
Amortized Cost		391.6	400.9
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax		4	2.4
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax		(2.4)	(0.4)
Debt Securities, Available-for-sale, Allowance for Credit Loss		0
Debt Securities, Available-for-sale		393.2	402.9
Fair Value, Recurring [Member] | Other Long-term Investments [Member] | Asset-backed Securities [Member]
Debt Securities, Available-for-sale [Line Items]
Amortized Cost		0.1	0.1
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax		0	0
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax		0	0
Debt Securities, Available-for-sale, Allowance for Credit Loss		0
Debt Securities, Available-for-sale		0.1	0.1
Fair Value, Recurring [Member] | Other Long-term Investments [Member] | Debt Securities [Member]
Debt Securities, Available-for-sale [Line Items]
Amortized Cost		0.1	0.1
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax		0	0
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax		0	0
Debt Securities, Available-for-sale, Allowance for Credit Loss		0
Debt Securities, Available-for-sale		0.1	0.1
Fair Value, Recurring [Member] | Short-term Investments [Member]
Debt Securities, Available-for-sale [Line Items]
Debt Securities, Available-for-sale	[1]	393.1	402.8
Fair Value, Recurring [Member] | Short-term Investments [Member] | Corporate Debt Securities [Member]
Debt Securities, Available-for-sale [Line Items]
Amortized Cost		199.2	203.2
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax		0.9	1.4
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax		(1.7)	(0.1)
Debt Securities, Available-for-sale, Allowance for Credit Loss		0
Debt Securities, Available-for-sale		198.4	204.5
Fair Value, Recurring [Member] | Short-term Investments [Member] | Municipal obligations [Member]
Debt Securities, Available-for-sale [Line Items]
Amortized Cost		14.3	11.5
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax		0.1	0.1
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax		0	0
Debt Securities, Available-for-sale, Allowance for Credit Loss		0
Debt Securities, Available-for-sale		14.4	11.6
Fair Value, Recurring [Member] | Short-term Investments [Member] | US Government Sponsored Agencies [Member]
Debt Securities, Available-for-sale [Line Items]
Amortized Cost		98.1	105.6
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax		2.8	0.7
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax		0	(0.2)
Debt Securities, Available-for-sale, Allowance for Credit Loss		0
Debt Securities, Available-for-sale		100.9	106.1
Fair Value, Recurring [Member] | Short-term Investments [Member] | Foreign Government Obligations [Member]
Debt Securities, Available-for-sale [Line Items]
Amortized Cost		5.6	4.7
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax		0	0
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax		0	0
Debt Securities, Available-for-sale, Allowance for Credit Loss		0
Debt Securities, Available-for-sale		5.6	4.7
Fair Value, Recurring [Member] | Short-term Investments [Member] | Foreign Government Debt [Member]
Debt Securities, Available-for-sale [Line Items]
Amortized Cost		2.1	3.1
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax		0	0
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax		0	0
Debt Securities, Available-for-sale, Allowance for Credit Loss		0
Debt Securities, Available-for-sale		2.1	3.1
Fair Value, Recurring [Member] | Short-term Investments [Member] | Asset-backed Securities [Member]
Debt Securities, Available-for-sale [Line Items]
Amortized Cost		72.2	72.7
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax		0.2	0.2
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax		(0.7)	(0.1)
Debt Securities, Available-for-sale, Allowance for Credit Loss		0
Debt Securities, Available-for-sale		71.7	72.8
Fair Value, Recurring [Member] | Short-term Investments [Member] | Debt Securities [Member]
Debt Securities, Available-for-sale [Line Items]
Amortized Cost		391.5	400.8
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax		4	2.4
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax		(2.4)	(0.4)
Debt Securities, Available-for-sale, Allowance for Credit Loss		0
Debt Securities, Available-for-sale		393.1	402.8
Fair Value, Recurring [Member] | Other Investments [Member]
Debt Securities, Available-for-sale [Line Items]
Debt Securities, Available-for-sale	[1]	$ 0.1	$ 0.1
[1]	Available-for-sale investments are included in the following accounts in the Condensed Consolidated Balance Sheets (in millions): March 31, 2020 December 31, 2019 Short-term investments $ 393.1 $ 402.8 Other investments 0.1 0.1 Total $ 393.2 $ 402.9

3. Amortized Cost and Fair Val

3. Amortized Cost and Fair Value of Debt Securities (Details) $ in Millions	Mar. 31, 2020USD ($)
Fair Value Disclosures [Abstract]
Mature in less than one year	$ 163.8
Mature in one to five years	167.3
Mature in more than five years	60.5
Total Amortized Cost	391.6
Mature in less than one year	163.9
Mature in one to five years	167.6
Mature in more than five years	61.7
Estimated Fair Value	$ 393.2

3. Fair Value and Gross Unreal

3. Fair Value and Gross Unrealized Losses with Unrealized Losses (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2020	Dec. 31, 2019
Price Change Debt Security	5.00%
Tolerable variance Level 2 debt security pricing	1.00%
Fair Value of Investments with Gross Unrealized Losses in loss position 12 months or more	$ 3.7	$ 19.9
Fair Value of Investments with Gross Unrealized Losses in loss position less than 12 months	161.2	91.9
Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss	0.1	0.1
Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax	164.9	111.8
Available-for-sale Securities, Continuous Unrealized Loss Position, Accumulated Loss	2.4	0.4
Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss	2.3	0.3
Corporate Debt Securities [Member]
Fair Value of Investments with Gross Unrealized Losses in loss position 12 months or more	0	2.1
Fair Value of Investments with Gross Unrealized Losses in loss position less than 12 months	106	46.5
Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss	0	0
Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax	106	48.6
Available-for-sale Securities, Continuous Unrealized Loss Position, Accumulated Loss	1.7	0.1
Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss	1.7	0.1
US Government Sponsored Agencies [Member]
Fair Value of Investments with Gross Unrealized Losses in loss position 12 months or more		10.8
Fair Value of Investments with Gross Unrealized Losses in loss position less than 12 months		27.5
Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss		0
Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax		38.3
Available-for-sale Securities, Continuous Unrealized Loss Position, Accumulated Loss		0.2
Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss		0.2
Asset-backed Securities [Member]
Fair Value of Investments with Gross Unrealized Losses in loss position 12 months or more	3.7	7
Fair Value of Investments with Gross Unrealized Losses in loss position less than 12 months	55.2	17.9
Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss	0.1	0.1
Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax	58.9	24.9
Available-for-sale Securities, Continuous Unrealized Loss Position, Accumulated Loss	0.7	0.1
Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss	0.6	$ 0
Fair Value, Recurring [Member] | Debt Securities [Member]
Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax	$ 2.4

3. Fair Value Financial Instru

3. Fair Value Financial Instruments (Details) - USD ($) $ in Millions	Mar. 31, 2020	Dec. 31, 2019
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Investment ownership percentage	37.00%
Interest Receivable, Current	$ 1.9	$ 2
Equity Securities without Readily Determinable Fair Value, Amount	0.5	0.3
Carrying (Reported) Amount, Fair Value Disclosure [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total long-term debt, excluding capital leases and current maturities	424.5	424.4
Fair Value, Inputs, Level 2 [Member] | Estimate of Fair Value, Fair Value Disclosure [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total long-term debt, excluding capital leases and current maturities	$ 422.9	$ 435.5

4. Intangible Assets, Goodwi_3

4. Intangible Assets, Goodwill and Other (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Dec. 31, 2019
Goodwill [Line Items]
Goodwill	$ 599,300	$ 599,300
Accumulated impairment loss	(335,200)	(335,200)
Goodwill, net	264,131	264,131
Goodwill, Acquired During Period	0
Life Science [Member]
Goodwill [Line Items]
Goodwill	250,100	250,100
Accumulated impairment loss	(41,800)	(41,800)
Goodwill, net	208,300	208,300
Goodwill, Acquired During Period	0
Clinical Diagnostics [Member]
Goodwill [Line Items]
Goodwill	349,200	349,200
Accumulated impairment loss	(293,400)	(293,400)
Goodwill, net	55,800	$ 55,800
Goodwill, Acquired During Period	$ 0

4. Intangible Assets, Goodwi_4

4. Intangible Assets, Goodwill and Other Intangible Assets (Details) - USD ($) $ in Millions	3 Months Ended		12 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Dec. 31, 2019	Oct. 01, 2019
Acquired Finite-Lived Intangible Assets [Line Items]
Goodwill, Acquired During Period	$ 0
Finite-Lived Intangible Assets, Net [Abstract]
Purchase Price	519.8		$ 525.6
Accumulated Amortization	(381.7)		(380.3)
Net Carrying Amount	138.1		145.3
Amortization [Abstract]
Amortization expense	5.9	$ 5.5
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles				$ 3.4
Intangible Assets, Gross (Excluding Goodwill)	$ 520		$ 525.8
Customer Relationships [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Remaining Amortization Period	6 years		6 years
Finite-Lived Intangible Assets, Net [Abstract]
Purchase Price	$ 105.1		$ 107.2
Accumulated Amortization	(74.5)		(74.3)
Net Carrying Amount	$ 30.6		$ 32.9
Know How [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Remaining Amortization Period	5 years		5 years
Finite-Lived Intangible Assets, Net [Abstract]
Purchase Price	$ 187		$ 188.5
Accumulated Amortization	(162.4)		(162.6)
Net Carrying Amount	$ 24.6		$ 25.9
Developed Technology Rights [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Remaining Amortization Period	8 years		8 years
Finite-Lived Intangible Assets, Net [Abstract]
Purchase Price	$ 142.1		$ 144.2
Accumulated Amortization	(94.4)		(93.9)
Net Carrying Amount	$ 47.7		$ 50.3
Licensing Agreements [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Remaining Amortization Period	8 years		8 years
Finite-Lived Intangible Assets, Net [Abstract]
Purchase Price	$ 76		$ 76
Accumulated Amortization	(45.2)		(44.4)
Net Carrying Amount	$ 30.8		$ 31.6
Trade Names [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Remaining Amortization Period	8 years		8 years
Finite-Lived Intangible Assets, Net [Abstract]
Purchase Price	$ 6.4		$ 6.4
Accumulated Amortization	(3.7)		(3.6)
Net Carrying Amount	$ 2.7		$ 2.8
Noncompete Agreements [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Remaining Amortization Period	5 years		6 years
Finite-Lived Intangible Assets, Net [Abstract]
Purchase Price	$ 3.1		$ 3.2
Accumulated Amortization	(1.4)		(1.4)
Net Carrying Amount	$ 1.7		$ 1.8
Other Intangible Assets [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Remaining Amortization Period	0 years		0 years
Finite-Lived Intangible Assets, Net [Abstract]
Purchase Price	$ 0.1		$ 0.1
Accumulated Amortization	(0.1)		(0.1)
Net Carrying Amount	0		0
In Process Research and Development [Member]
Amortization [Abstract]
Indefinite-lived Intangible Assets (Excluding Goodwill)	$ 0.2		$ 0.2

5. Supplemental Cash Flow In_3

5. Supplemental Cash Flow Information (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Supplemental Cash Flow Elements [Abstract]
Net Income Attributable to Parent	$ 685,912	$ 865,195
Depreciation and Amortization	33,600	32,900
Right-of-use asset amortization	9,600	10,000
Share-based Payment Arrangement, Noncash Expense	9,700	8,500
(Gain) Loss on Sale of Securities, Net	(400)	0
Other than Temporary Impairment Losses on Investments	0	1,600
Changes in fair market value of equity securities	(827,700)	(1,059,200)
Loss on Disposition of Property Plant Equipment	100	300
Changes in fair value of contingent consideration	(100)	(500)
Payments for operating lease liabilities	(9,300)	(11,700)
Decrease in accounts receivable	2,200	(2,000)
Increase in inventories	(13,700)	(11,600)
Increase in other current assets	(9,500)	(16,700)
(Decrease) increase in accounts payable and other current liabilities	(25,600)	20,600
Decrease in income taxes payable	20,900	13,800
Increase in deferred income taxes	171,800	238,500
Increase in other long term liabilities	15,700	(38,300)
Other	(400)	(8,500)
Net cash provided by operating activities	62,808	42,943
Noncash or Part Noncash Acquisition, Fixed Assets Acquired	6,000	5,100
Noncash or Part Noncash Acquisition, Investments Acquired	$ 2,700	$ 0

6. Long-Term Debt (Details)

6. Long-Term Debt (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Dec. 31, 2019	Dec. 31, 2010
Debt Instrument [Line Items]
Debt and Lease Obligation	$ 438,500	$ 439,800
Other Long-term Debt, Current	426,300	426,200
Long-term debt, net of current maturities	12,205	13,579
Unsecured Debt [Member] | Senior Notes 4.875% due 2020 [Member]
Debt Instrument [Line Items]
Unsecured Debt	425,000	425,000
Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net	$ 500	600
Debt Instrument, Interest Rate, Stated Percentage			4.875%
Debt Instrument, Redemption Price, Percentage	100.00%
Long-term debt	$ 424,500	424,400	$ 422,600
Debt Instrument, Interest Rate, Effective Percentage			4.946%
Face amount of debt sold			$ 425,000
Finance Lease Obligations [Member] | Finance Leases and Other Debt [Member]
Debt Instrument [Line Items]
Other Long-term Debt	14,000	$ 15,400
Line of Credit [Member]
Debt Instrument [Line Items]
Line of credit maximum borrowing capacity	200,000
Outstanding borrowings	$ 0
Line of Credit Facility, Interest Rate at Period End	2.555%
Standby Letters of Credit [Member]
Debt Instrument [Line Items]
Line of credit maximum borrowing capacity	$ 200

7. Accumulated Other Compreh_3

7. Accumulated Other Comprehensive Income 7. Accumulated Other Comprehensive Income (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning balance, Accumulated other comprehensive income	$ (87,348)
Total other comprehensive income (loss) net of tax	(61,607)	$ (34,007)
Ending balance, Accumulated other comprehensive income	(148,955)
Other (income) expense, net	(3,273)	(18,696)
Accumulated Translation Adjustment [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning balance, Accumulated other comprehensive income	(72,400)	(35,500)
Other Comprehensive Income (Loss), before Reclassifications, before Tax	(62,900)	(36,400)
Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax	0	0
Other Comprehensive Income (Loss), Tax	900	0
Total other comprehensive income (loss) net of tax	(62,000)	(36,400)
Ending balance, Accumulated other comprehensive income	(134,400)	(71,900)
Accumulated Defined Benefit Plans Adjustment [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning balance, Accumulated other comprehensive income	(22,200)	(14,800)
Other Comprehensive Income (Loss), before Reclassifications, before Tax	200	200
Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax	300	200
Other Comprehensive Income (Loss), Tax	200	0
Total other comprehensive income (loss) net of tax	700	400
Ending balance, Accumulated other comprehensive income	(21,500)	(14,400)
Accumulated Defined Benefit Plans Adjustment [Member] | Reclassification Out Of Accumulated Other Comprehensive Income [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Other (income) expense, net	(300)	(200)
Accumulated Net Unrealized Investment Gain (Loss) [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning balance, Accumulated other comprehensive income	7,200	3,300
Other Comprehensive Income (Loss), before Reclassifications, before Tax	0	2,000
Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax	(400)	0
Other Comprehensive Income (Loss), Tax	100	0
Total other comprehensive income (loss) net of tax	(300)	2,000
Ending balance, Accumulated other comprehensive income	6,900	5,300
Accumulated Net Unrealized Investment Gain (Loss) [Member] | Reclassification Out Of Accumulated Other Comprehensive Income [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Other (income) expense, net	(400)	0
AOCI Attributable to Parent [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning balance, Accumulated other comprehensive income	(87,400)	(47,000)
Other Comprehensive Income (Loss), before Reclassifications, before Tax	(62,700)	(34,200)
Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax	(100)	200
Other Comprehensive Income (Loss), Tax	1,200	0
Total other comprehensive income (loss) net of tax	(61,600)	(34,000)
Ending balance, Accumulated other comprehensive income	$ (149,000)	$ (81,000)

8. Earnings Per Share (Details

8. Earnings Per Share (Details) - shares shares in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Basic weighted average shares outstanding	29,865	29,801
Effect of potentially dilutive stock options and restricted stock awards	331	303
Diluted weighted average common shares	30,196	30,104
Anti-dilutive shares	62	226

9. Other Income and Expenses_2

9. Other Income and Expenses (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Interest and investment income	$ (2,800)	$ (19,500)
Net realized (gain) loss on investments	(400)	0
Other than Temporary Impairment Losses on Investment	0	1,600
Other Nonoperating Income	(100)	(800)
Other Nonoperating Income (Expense)	$ 3,273	$ 18,696

10. Income Taxes (Details)

10. Income Taxes (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Dec. 31, 2019
Effective tax rate	23.70%	23.20%
Unrecognized Tax Benefits	$ 51.7		$ 39.2
Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions	$ 12.5

Segment Reporting (Details)

Segment Reporting (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Segment Reporting Information [Line Items]
Net sales	$ 571,644	$ 553,979
Income before income taxes	898,699	1,127,266
Life Science [Member]
Segment Reporting Information [Line Items]
Net sales	227,200	215,700
Income before income taxes	25,400	22,800
Clinical Diagnostics [Member]
Segment Reporting Information [Line Items]
Net sales	340,300	334,100
Income before income taxes	46,200	30,900
Other Segments [Member]
Segment Reporting Information [Line Items]
Net sales	4,100	4,200
Income before income taxes	$ 700	$ (100)

11. Segment Information Segm_3

11. Segment Information Segment Profit Reconciliations (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Income before income taxes	$ 898,699	$ 1,127,266
Marketable Securities, Unrealized Gain (Loss)	827,671	1,059,230
Operating Segments [Member]
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Income before income taxes	72,300	53,600
Corporate, Non-Segment [Member]
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Income before income taxes	(3,700)	(2,900)
Segment Reconciling Items [Member]
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Marketable Securities, Unrealized Gain (Loss)	827,700	1,059,200
Foreign Currency Gain (Loss) [Member] | Segment Reconciling Items [Member]
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Income before income taxes	(900)	(1,300)
Other Nonoperating Income (Expense) [Member] | Segment Reconciling Items [Member]
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Income before income taxes	$ 3,300	$ 18,700

11. Segment Information Segm_4

11. Segment Information Segment Asset Reconciliation (Details) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Segment Reporting, Asset Reconciling Item [Line Items]
Assets	$ 8,684,359	$ 8,008,859

13. Restructuring Costs (Detail

13. Restructuring Costs (Details) - USD ($) $ in Millions	3 Months Ended	5 Months Ended	16 Months Ended
	Mar. 31, 2020	Mar. 31, 2020	Mar. 31, 2020	Dec. 31, 2019
Facility Closing [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve	$ 2.9	$ 2.9	$ 2.9	$ 3.2
Restructuring Charges			4
Restructuring Reserve, Accrual Adjustment	0
Payments for Restructuring	(0.3)
Facility Closing [Member] | Accounts Payable and Accrued Liabilities [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve, Current	2.7	2.7	2.7
Facility Closing [Member] | Other Current Liabilities [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve, Current	0.2	0.2	0.2
European and North American Reorganization [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve	14	14	14	25.3
Restructuring Charges		22.9
Restructuring Reserve, Accrual Adjustment	(2.4)
Payments for Restructuring	(8.6)
Restructuring Reserve, Foreign Currency Translation (Gain) Loss	(0.3)
European and North American Reorganization [Member] | Cost of Goods and Service Benchmark [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve, Accrual Adjustment	(1.5)
European and North American Reorganization [Member] | Selling, General and Administrative Expenses [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve, Accrual Adjustment	(0.5)
European and North American Reorganization [Member] | Research and Development Expense [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve, Accrual Adjustment	(0.4)
European and North American Reorganization [Member] | Life Science [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve	2.9	2.9	2.9	6.2
Restructuring Reserve, Accrual Adjustment	(0.3)
Payments for Restructuring	(2.9)
Restructuring Reserve, Foreign Currency Translation (Gain) Loss	(0.1)
European and North American Reorganization [Member] | Clinical Diagnostics [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve	11.1	$ 11.1	$ 11.1	$ 19.1
Restructuring Reserve, Accrual Adjustment	(2.1)
Payments for Restructuring	(5.7)
Restructuring Reserve, Foreign Currency Translation (Gain) Loss	$ (0.2)

14. Leases (Details)

14. Leases (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Dec. 31, 2019
Lessee, Lease, Description [Line Items]
Other Commitment	$ 1,600
Finance Lease, Right-Of-Use Asset, before Accumulated Amortization	11,400		$ 11,400
Finance Lease, Right-Of-Use Asset, Accumulated Amortization	4,300		4,200
Finance Lease, Right-Of-Use Asset, after Accumulated Amortization	$ 7,100		$ 7,200
Lessee, Operating Lease, Lease Not yet Commenced, Term of Contract	4 years
Lessee, Operating Lease, Liability, Payments, Remainder of Fiscal Year	$ 32,000
Finance Lease, Liability, Payments, Remainder of Fiscal Year	$ 1,200
Operating Lease, Weighted Average Remaining Lease Term	9 years		9 years
Finance Lease, Weighted Average Remaining Lease Term	18 years		18 years
Operating Lease, Weighted Average Discount Rate, Percent	4.10%		4.20%
Finance Lease, Liability, Current	$ 500		$ 500
Finance Lease, Liability, Noncurrent	11,000		11,200
Finance Lease, Liability	$ 11,500		$ 11,700
Finance Lease, Weighted Average Discount Rate, Percent	6.50%		6.50%
Lessee, Operating Lease, Liability, Payments, Due Year Two	$ 37,700
Finance Lease, Liability, Payments, Due Year Two	1,200
Lessee, Operating Lease, Liability, Payments, Due Year Three	30,500
Finance Lease, Liability, Payments, Due Year Three	1,100
Lessee, Operating Lease, Liability, Payments, Due Year Four	25,700
Finance Lease, Liability, Payments, Due Year Four	1,100
Lessee, Operating Lease, Liability, Payments, Due Year Five	23,000
Finance Lease, Liability, Payments, Due Year Five	1,100
Lessee, Operating Lease, Liability, Payments, Due after Year Five	105,000
Finance Lease, Liability, Payments, Due after Year Five	14,900
Lessee, Operating Lease, Liability, Payments, Due	253,900
Finance Lease, Liability, Payment, Due	20,600
Lessee, Operating Lease, Liability, Undiscounted Excess Amount	(44,000)
Finance Lease, Liability, Undiscounted Excess Amount	(9,100)
Operating lease right-of-use assets	200,487		$ 201,868
Operating Lease, Payments	11,400	$ 11,700
Operating Lease, Cost	12,600	12,400
Finance Lease, Right-of-Use Asset, Amortization	100	100
Finance Lease, Interest Expense	200	200
Finance Lease Cost	300	300
Sublease Income	700	700
Finance Lease, Interest Payment on Liability	200	200
Finance Lease, Principal Payments	100	200
Right-of-Use Asset Obtained in Exchange for Operating Lease Liability	10,800	1,400
Right-of-Use Asset Obtained in Exchange for Finance Lease Liability	0	$ 0
Current operating lease liabilities	34,440		35,365
Operating lease liabilities	175,452		176,018
Operating Lease, Liability	$ 209,900		$ 211,400
Minimum [Member]
Lessee, Lease, Description [Line Items]
Lessee Operating And Finance Leases Remaining Lease Term	1 year
Maximum [Member]
Lessee, Lease, Description [Line Items]
Lessee Operating And Finance Leases Remaining Lease Term	19 years

15. Subsequent Events (Details)

15. Subsequent Events (Details) - USD ($)	Apr. 09, 2020	Apr. 01, 2020	Dec. 31, 2019
Subsequent Event [Line Items]
Business Combination, Consideration Transferred			$ 4,200,000
Subsequent Event [Member]
Subsequent Event [Line Items]
Proceeds from Divestiture of Businesses		$ 12,200,000
Business Combination, Consideration Transferred	$ 100,000,000
Sales milestone minimum amount [Member] | Subsequent Event [Member]
Subsequent Event [Line Items]
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, Low		0
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High		$ 60,000,000